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ABSTRACT 
  
Cancer continues to be a major health burden worldwide, with millions of new cases being 
diagnosed each year. Among women breast cancer remains a leading cause of cancer-related 
morbidity and mortality globally, despite the significant advances in detection and 
individualised treatments. The ideal non-surgical approach for the treatment of breast cancer 
would be anticancer therapeutics that are delivered directly to the tumour site for complete 
elimination of cancerous cells without being toxic to surrounding healthy cells. However, 
current chemotherapeutics encounter numerous challenges due to adverse side effects and 
progressive drug resistance albeit effective. In light of this, identifying new effective therapies 
with minimal toxic and chemosensitizing effects as well as target specificity is crucial in 
combating cancer. Emerging evidence has supported the use of plant-derived chemicals as 
novel alternative treatment options, owing to their minimal side effects and toxicity.    
Plant-derived polyphenols have gained considerable research interest due to their ability to 
inhibit proliferation, initiate apoptosis and arrest the cell cycle of cancerous cells by modulating 
related pathways. Furthermore, incorporation of active plant-derived polyphenols into novel 
technologies such as nanosystems, offers more optimal therapies through improved 
bioavailability and target specificity. In this regard, this study demonstrates, for the first time, 
the potential of phytochemicals isolated from the methanolic extract of the medicinal plant, 
Eriocephalus africanus, as an alternative therapeutic strategy in breast cancer treatment using 
ER-positive human adenocarcinoma (MCF-7) cell lines. Spectroscopic techniques including 
nuclear magnetic resonance spectroscopy (NMR), infrared spectroscopy (IR) and mass 
spectrometry (MS) were used to identify the isolated compounds as hesperidin (flavanone), 
luteolin (flavone) and apigenin (flavone). Preliminary anticancer screening using the 3-
(4,5dimethylthiazolyl)-2,5-diphenyl-tetrazolium bromide (MTT) assay revealed hesperidin 
and luteolin to be potent against MCF-7.   
Dysregulated cellular apoptotic death is a hallmark of cancer and chemotherapy resistance; 
thus, the development of anticancer drugs targeting apoptosis is a widely used, effective 
anticancer treatment strategy. In this study, the efficacy of hesperidin and luteolin in targeting 
the apoptotic pathway was evaluated. Treatment of breast cancer cells with hesperidin and 
luteolin resulted in the downregulated expression of key anti-apoptotic Bcl-2; upregulated 
xiv  
  
expression of pro-apoptotic Bax and caspases -8, -9 and -3. In addition, hesperidin and luteolin 
demonstrated the ability to effect epigenetic control through altering the expression of apoptotic 
microRNAs (-16, -21 and -34a). Moreover, treatment with hesperidin and luteolin resulted in 
significant accumulation of MCF-7 apoptotic cells into the G0/G1 and sub-G1 cell cycle 
phases, respectively. Encapsulation of hesperidin into nanoemulsions improved the cytotoxic 
and apoptotic effects in MCF-7 without being cytotoxic to non-cancerous human cell lines 
(HEK 293), halted the progression of the MCF-7 cells in the G2/M phase, and exhibited 
potential therapeutic activity through inhibiting the expression of oncomirs miR-21 and -155 
overexpressed in breast cancer. Encapsulation of luteolin into solid nanoparticles generated 
from cleaved stearylamine exhibited non-selective cytotoxicity and decreased cell viability (< 
10%) in both MCF-7 and HEK 293 cells, thus no further investigations were conducted using 
luteolin-loaded solid nanoparticles. Collectively, findings from this study provide new 
evidence on the effects of flavonoids isolated from E. africanus on apoptotic and epigenetic 
control in breast cancer, increasing our knowledge of the molecular basis of their anticancer 
activity.  
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 1.  CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW  
  
1.1 Background  
  
Cancer is a rapidly growing disease with the number of deaths increasing considerably 
worldwide, as it is estimated that by 2025, 20 million new cases would emerge in low- and 
middle-income countries [1]. Currently, approximately 70% of cancer deaths occur in low- and 
middle-income countries, with prostate, breast, colorectal and lung being the most common 
cancers. In men, the most prevalent cancer types occur in the prostate, lung, colon, and rectum, 
while in women, breast, lung, uterine, and thyroid cancers are more prevalent [2, 3]. According 
to GLOBOCAN, in 2018, approximately 2 093 876 (lung), 2 088 849 (breast), 1 849 518 
(colorectum) and 1 276 106 (prostate) new cases were recorded worldwide [4]. Overall, the 
data suggests that breast and prostate cancer present with the highest occurrences, globally.  
Despite the major advances made in medicine towards cancer treatment, cancer remains a 
public health concern. Current effective treatments, including chemotherapy and radiotherapy, 
are often hampered by adverse side effects coupled with progressive chemoresistance [5]. 
Plant-derived compounds have gained importance as potential alternative treatments for cancer 
with minimal side effects and anti-proliferative and pro-apoptotic properties [6]. Another 
drawback in current cancer treatment approaches, is the lack of specificity in drug targeting. 
Therefore, the application of nanotechnology to drug modification and drug delivery systems 
have emerged as a promising new therapeutic approach offering improved bioavailability, 
increased accumulation of drugs at specific disease sites, and overall enhanced efficacy in 
cancer treatment [3].  
 
1.2 Definition and classification of cancer  
  
Cancer can be described as a group of diseases in which cells abnormally hyper-proliferate, 
invade normal tissue and eventually spread to the rest of body through blood and the lymphatic 
system [7]. Cancer is a result of progressive genetic and epigenetic alterations within the cell 
that leads to uncontrolled cell proliferation associated with evasion of apoptosis, lack of cell 
cycle arrest, tumour progression and metastasis [1, 8]. Cancer is classified based on the tissue 
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type or location of origin, for example, cancers originating in the breast, lung and liver are 
called breast, lung and liver cancer, respectively [9]. Histological classification broadly 
categorise cancer into; (1) carcinomas, which are cancers that develop from the epithelial tissue 
lining organs or of the skin  (2) sarcomas,  malignant tumours in connective tissue such as bone 
and cartilage, muscle and fat cells; (3) leukaemia referred to as blood or liquid cancers, 
originating from blood-forming tissue such as bone marrow;  (4) lymphomas, malignancies 
arising from the nodes or glands of the lymphatic system; and (5) myeloma originating from 
the plasma cells of bone marrow [10, 11]. Tumours can be malignant or benign. Benign tumours 
are slow-growing, non-cancerous and non-invasive. In contrast, malignant tumours are 
cancerous, invasive and metastatic [11].  
 
1.2.1 Aetiology and pathogenesis of cancer   
   
The pathogenesis of cancer is multifactorial involving a network of complex mechanisms that 
are not yet fully understood with each systemic representation shedding more light to the 
understanding of the disease [12]. Presently, irrespective of the cancer type, the basis of cancer 
pathogenesis is commonly accepted to arise from genetic damage or alterations in gene 
expression (mediated by epigenetic mechanisms), within a normal single cell that gives rise to 
its transformation into a malignant or tumour cell [12, 13]. Several studies have shown that the 
genomic abnormalities may be induced or initiated by various risk factors including inherited 
genetic predispositions, random spontaneous DNA replication errors, external factors 
collectively known as carcinogens (e.g. chemicals, radiation and viruses), or other factors such 
as tobacco smoke, physical inactivity and an unhealthy diet [13,14]. Consequently, the 
genetic/epigenetic damage may lead to mutations in key genes such as tumour suppressors, 
oncogenes, or genes controlling the cell cycle, resulting in inactivation of normal cell growth 
control and promotion of abnormal cell proliferation, eventually giving rise to cancer [15].   
Experimental evidence has demonstrated that the progression of a genetically altered cell to a 
malignant tumour, though characterised by various pathways and distinct histological features 
for each cancer type, is a multi-step process consisting of initiation, promotion and progression 
[15]. As shown in Figure 1, a single cell initially acquires genetic mutations triggered by 
various stimuli (initiators) and becomes predisposed for neoplastic transformation. The 
mutated cell proceeds to the lengthy promotion stage where it abnormally proliferates and 
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reproduces many of its kind (clonal expansion); histologically this condition is called 
hyperplasia (increase in cell number). Through the progression stage the mutated cells, acquire 
new mutations, continue to proliferate, change form and grow in tumour size (in situ cancer) 
[13,16,17]. The in-situ tumours may remain dormant or acquire other mutations, progress to 
invade surrounding tissue and become invasive (malignant tumours) [16].  
  
 
Figure 1. The stages of cancer development: initiation, promotion and progression. The initiation may 
be triggered by different factors or stimuli including spontaneous errors in DNA replication and various 
carcinogens. Once initiated the alerted cell acquires the potential to transform from normal to a 
malignant tumour (Adapted from Kolat et al. 2019 [17]).   
  
Consequently, as the malignant tumours continue to rapidly proliferate, they outgrow the 
oxygen and nutrient supply of their host tissue vasculature and become oxygen-deprived 
(hypoxia). Therefore, to sustain this abnormal growth, tumours stimulate the growth of new 
blood vessels for their own supply through a process called angiogenesis [18]. In addition to 
maintaining the tumour oxygen and nutrient supply, and waste disposal, angiogenesis enables 
the tumour cells to invade surrounding tissue and metastasise to distant sites by providing an 
escape route into the circulation via the newly formed blood and lymph systems [19, 20].   
 1.3 Role of apoptosis in cancer  
Apoptosis is a highly organised cell death mechanism essential for healthy tissue development 
and homeostasis [21]. It serves to remove abnormally proliferating, and/or irreparable DNA 
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damaged cells, thus protecting genomic integrity and preventing carcinogenesis [22]. 
Morphological characteristics of apoptosis include nuclear changes such as chromatin 
condensation, nuclear fragmentation and breakdown, and overall changes such as cellular 
rounding and shrinkage, volume reduction and blebbing [23]. Apoptosis can be induced by 
different stimuli, through both intracellular and extracellular signals [24]. This process is 
initiated and activated by a family of intracellular proteins known as cysteine aspartate-specific 
proteases (caspases) and regulated by the Bcl-2 family of proteins.  
  
1.3.1 The Bcl-2 family proteins and caspases  
  
The Bcl-2 protein cluster controls cell death mainly through release of cytoplasmic cytochrome 
c and subsequent activation of caspases resulting in mitochondrial apoptosis [25]. The Bcl-2 
family is divided into pro-apoptotic effectors (Bax, Bak); pro-apoptotic BH3-only proteins 
(Bad, Bid, Bik, Bim, Noxa, Puma) and anti-apoptotic proteins (Bcl-2, Bcl-xL, Bcl-W, Mcl-1, 
Bfl-1/A1) [26, 27]. Anti-apoptotic proteins inhibit apoptosis by preventing the release of 
mitochondrial cytochrome c mediated via Bax and Bad, while pro-apoptotic proteins promote 
apoptosis by triggering the release of cytochrome c into the cytoplasm [25, 28]. Overall, the 
balance between pro- and anti-apoptotic proteins determine the fate of the cell; when 
proapoptotic proteins dominate, apoptosis is induced, while the opposite response causes 
inhibition [29].  
Caspases are a family of cysteine proteases, whose subclassification is based on their distinct 
function within apoptosis, viz. either as initiator caspases (caspase -2, -8, -9, and -10) or effector 
caspases (-3, -7, and -6) [30, 31]. Caspases usually exist inside the cell, in their inactive form, 
as procaspases. Upon sensing death signals, initiator caspases initiate apoptosis through 
cleavage of procaspases into active effector caspases, which mediate cellular degradation 
through proteolysis, leading to cell death [31]. Activation of initiator caspase-8 normally leads 
to death receptor-mediated apoptosis, while activation of caspase-9 leads to mitochondria-
mediated cell death [32].   
 
1.3.2 Molecular mechanisms of the apoptotic pathway   
  
The apoptotic pathway is initiated by two distinct pathways known as the intrinsic  
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(mitochondrial) and extrinsic (death receptor). The intrinsic pathway is regulated by the Bcl-2 
gene family and involves mitochondrial degradation. It is initiated by various external and 
internal stimuli, including chemotherapy, DNA damage, oxidative and oncogenic stress, an 
excess of calcium cations, hypoxia, and growth factor withdrawal (Figure 2) [24]. The stimuli 
produce intracellular signals, leading to the activation of Bax and Bad, which accumulate at the 
mitochondrial outer membrane, oligomerise and mediate mitochondrial outer membrane 
permeabilization (MOMP), through pore formation and membrane potential changes (∆Ψm). 
The permeabilization results in the release of cytochrome c, which then forms an apoptosome 
with apoptotic protease-activating factor-1 (APAF-1), dATP, and procaspase-9. Subsequently, 
procaspase-9 is converted to caspase-9, which activates the executioner caspases, which in turn 
coordinate cell death (apoptosis) [5, 24, 33].   
In contrast, the extrinsic (death receptor) pathway is initiated by extracellular death receptors, 
such as tumour necrosis factor (TNF), death receptor 5 (DR5) and Fas,  which bind to their 
respective ligands, viz. TNF,  TNF related apoptosis-inducing ligand (TRAIL), and Fas ligand 
(FasL) [34]. Upon binding to these ligands, death receptors trimerize and promote the binding 
of adaptor proteins, such as Fas-associated DD protein (FADD) and TNF receptor-associated 
death domain (TRADD), to initiator procaspases -8 and -10, leading to the formation of the 
death-inducing signalling complex (DISC). DISC consists of FADD as an adaptor molecule, 
the cellular FLICE inhibitory proteins (c-FLIPs), procaspase-8 and -10; and its formation leads 
to the activation of caspase-8 and -10, which promotes apoptosis through direct cleavage of 
downstream effector caspases such  as caspase-3 [35, 36]. The extrinsic and intrinsic pathways 
may crosstalk through the caspase-8 activated cleavage of BH3 interacting-domain death 
agonist (Bid) to tBid, which targets the mitochondria and activates the pro-apoptotic proteins 
Bax and Bak, facilitating the continuation of the intrinsic pathway [24].    
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Figure 2. The intrinsic (mitochondrial) and extrinsic (death receptor) apoptotic pathways.  
The intrinsic pathway is triggered by intracellular and extracellular stimuli that activates Bax and Bak. 
Activation of Bax and Bak causes MOMP and subsequent release of cytochrome c and formation of an 
apoptosome followed by activation of caspase 9. Caspase 9 activates the executioner caspases 3/6/7, 
that in turn coordinate cell death (apoptosis). The extrinsic pathway is initiated through the binding of 
specific death receptors to their ligands followed by activation of caspase 8, which propagates apoptotic 
cell death through direct cleavage of downstream effector caspases 3/6/7 (Adapted from Baig et al. 2016 
[37]).  
 
  
  
7  
  
1.3.3 Apoptosis and cancer progression   
  
Dysregulation of apoptosis has been implicated in the pathophysiology of various diseases, 
including cancer, AIDS and degenerative diseases [5]. It is clear that progression of cancer is 
influenced by lack of apoptotic function or evasion of apoptosis resulting in malignant cells not 
dying [22, 28]. The ability of cancer cells to evade apoptosis is a hallmark of the disease, which 
promotes uncontrolled propagation of cells resulting in tumour survival, treatment resistance 
and cancer recurrence [38]. Cancer cells may evade apoptosis through several mechanisms, 
including overexpression of anti-apoptotic Bcl-2 genes and oncogenes, downregulation of pro-
apoptotic Bcl-2 genes and loss of caspase activity [5].   
Overexpression of prominent anti-apoptotic genes, Bcl-2, Bcl-xL, and Mcl-1, have been 
implicated in apoptosis evasion and treatment resistance in various cancers, including breast, 
lung and colorectal [39]. Repression of Bcl-2 in breast cancer has been reported to sensitise 
cells for treatment and promotes apoptosis [40–42]. Additionally, Bcl-xL/Mcl-1 inhibitors have 
been successful in inducing cell death even in most aggressive forms of breast cancer such as 
triple-negative breast cancer [43]. Notably, inactivation of BH3-only members (Bad, Puma, 
Noxa), and caspases have been shown to promote resistance to pro-apoptotic stimuli and 
tumour proliferation in vivo [44]. Furthermore, since miRNA regulates gene expression in 
cellular processes, their dysregulation could promote overexpression of anti-apoptotic genes 
and promote evasion [45, 46]. Hence, inducing or restoring apoptotic function has emerged as 
an effective approach in preventing cancer progression.  
  
1.4 Cell cycle regulation and cancer  
  
Regulated cellular progression through the cell cycle is essential for maintaining ordered DNA 
replication, cell division and tissue integrity. The cycle is regulated by specific classes of 
proteins (cyclins and cyclin-dependent kinases Cdks) and consists of four phases (Figure 3)  
denoted as 1) G1, where the cells grow and reorganise organelles in preparation for DNA 
replication, 2) S phase,  synthesis phase, cell replicates or copies its DNA  3) G2, second growth 
phase, cells grow and accumulates proteins for mitosis 4) Mitotic phase, the cell division occurs  
[47]. Progression of the cell from one phase to another is regulated by a series of checkpoints 
that ensure all conditions and requirements are met before the cell commits to the next phase. 
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For example, the G2 checkpoint prevents transition to mitosis if DNA replication is incomplete, 
by holding the cell in-phase (cell cycle arrest) until all DNA replication is complete. Another 
vital checkpoint occurs in the M phase, which prevents cell division (mitosis arrest) in response 
to improper alignment of the daughter chromosomes on the mitotic spindle. The G1 checkpoint 
also inhibits transition into the S phase in the presence of prior DNA damage and leads to G1 
cell cycle arrest until the DNA is repaired [48]. In cases of severe unrepairable DNA or 
prolonged mitotic arrest, cells commit to apoptotic, autophagic, or necrotic cell death [49, 50].   
  
Figure 3. The progression of the cell through the cell cycle. G0 denotes the phase where nondividing 
cells enter, this is not necessarily permanent as in some cases cells re-enter the cycle. G1 the first growth 
phase, S synthesis phase, G2 second growth phase, M denotes mitosis where the cell divides and 
cytokinesis the separation of the cytoplasm (Adapted from Introduction to the Cell Cycle 2017 p. 648 
[48]).  
  
However, in cancer pathogenesis, cancer cells often acquire genetic and epigenetic mutations 
that disable checkpoints, impair the ability to induce cell cycle arrest, and allow progression of 
cancer cells through the cycle despite their multiple genome impairments. This sustained 
progression promotes uncontrolled proliferation of cancer cells with defective genomes and 
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often results in tumour metastasis and treatment resistance. Thus, anticancer approaches that 
promote cell cycle arrest and subsequent cell death, show promising potential in cancer 
treatment [51]. Different cytotoxic stimuli have been successful in halting breast cancer cell 
progression at different cycle phases, leading to apoptosis, such as G2/M phase [52], S and 
G2/M phase [53], G1/M [54], and S phase [55].  
  
1.5 Role of microRNA in cancer  
  
MicroRNAs (miRNA) have recently gained recognition as key post-transcriptional regulators 
of several cellular signalling processes, including apoptosis, cell cycle and proliferation [56]. 
MiRNA are small non-coding RNA, approximately 18-24 nucleotides in length, that regulate 
gene expression through binding to the 3′ untranslated region (3′ UTR) of the target mRNA, 
resulting in either mRNA degradation or inhibition of translation [57]. The inhibition of mRNA 
translation or its degradation depends on the extent of mRNA-miRNA nucleotide sequence 
complementarity; perfect matching leads to mRNA degradation, whereas partial matching or 
mismatch results in inhibition of translation [58]. The biosynthesis and mechanisms of miRNA 
regulation of their target mRNA are shown in Figure 4. Briefly, the miRNA gene is first 
transcribed by RNA polymerase II into a long primary miRNA, then processed by 
Drosha/DGCR8  microprocessor complex into 70 -120 nucleotide long precursor miRNA (pre- 
miRNA) possessing a stem-loop structure and a 2-nucleotide overhang at the 3′- cleavage end 
[45, 59]. The precursor miRNA is then transferred into the cytoplasm by binding to a Ran-
dependent nuclear transport receptor protein, exportin 5 [59]. Following transfer into the 
cytoplasm, the pre-miRNA is processed into mature RNA duplexes (20-22 nucleotides) by the 
Dicer/TRBP/PACT complex [56]. By helicase action, the duplex RNA is separated into single 
miRNA strands. The thermodynamic stability of the duplex 5′- end influences the separation 
of the strands. Normally the miRNA strand that is unstable at 5′-end is incorporated into the 
RNA-induced silencing complex (RISC) and guides the miRNA-induced silencing complex 
(miRISC) to mismatch pairing with the target mRNA, resulting in translation inhibition. The 
strand that is at the stable 5′- end is usually degraded. Therefore, miRNA negatively regulates 
the expression of their target mRNA [56, 59].  
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Figure 4. The biosynthesis of miRNA and the mechanisms of their regulation of target mRNA. The 
solid arrows indicate the classical pathway which includes Drosha, whereas the dotted lines indicate 
the non-classical Drosha-independent way (Adapted from Si et al. 2019 [56]).  
  
Recent evidence has indicated that the expression of miRNAs is dysregulated in various human 
cancers. MiRNAs function as either oncogenes or tumour suppressors by regulating the 
expression of fundamental target genes [60]. MicroRNAs from the miR-15a/16 cluster have 
been shown to act as tumour suppressors, inhibiting cell proliferation, promoting cell cycle 
arrest and apoptosis [61]. MiR-15a/16 is often silenced or deleted in various cancer types. 
Previous studies have demonstrated that miR15a/16 function by targeting oncogenes such as  
Bcl-2, Mcl-1 and cell cycle regulatory genes such as Cyclin D1 [62]. Downregulation of 
miR15a/16-1 have been indicated to contribute to the pathogenesis of many cancers including 
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breast cancer, prostate cancer and chronic lymphocytic leukaemia [62–64]. Activation of 
miR15a and -16 in breast cancer have been shown to downregulate Bcl-2 expression and trigger 
apoptosis [65]. In MDA-MB-231 breast cancer cells, miR-15a expression was found to be 
significantly low and upregulation inhibited cell growth and induced G1 cell cycle arrest [63].   
MiR-34a is also regarded as a tumour suppressor in human cancer and is often lowly expressed 
as well. Low miR-34a expression has been correlated with poor overall survival in triple 
negative breast and lung cancer patients, and with metastasis in breast cancer cells [66, 67]. 
Notably, the upregulation of miR-34a expression is associated with disease-free survival in 
cancer [60], promotion of apoptosis and cell cycle arrest in osteosarcoma [68], and sensitisation 
of MC7/ADR cells to doxorubicin treatment [69].  
MiRNA such as miR-21 and miR-155 promote cancer progression by inhibiting expression of 
tumour suppressor genes and are classified as miRNA oncogenes (oncomiRs) [59]. OncomiRs 
are often overexpressed and exhibit oncogenic activity in human cancer [70]. In addition, 
downregulation of miR-21 and miR-155 has been shown to correlate with upregulation of 
proapoptotic Bid of Bcl-2 family, caspase-9, increased apoptosis and reduced cell proliferation 
in cancer cells [71].   
  
1.6 Breast Cancer  
  
1.6.1 Definition and classification  
  
Breast cancer is a complex heterogeneous disease resulting from uncontrolled division and 
proliferation of the cells lining the mammary glands and ducts [58]. Histologically, breast 
cancer is broadly classified as either non-invasive (carcinoma in situ, which is further 
subdivided as ductal or lobular), or invasive (infiltrating carcinoma, subtypes include; invasive 
ductal, invasive lobular, ductal lobular, mucinous, tubular, papillary and medullary) [72]. In 
keeping with this, over the past 10 years, breast cancer treatment strategies have evolved into 
more biologically specific therapies, and hence increasingly, the molecular heterogeneity of the 
disease is now incorporated into a classification scheme [73]. Recent molecular classifications 
divide breast carcinomas into five groups; luminal A, luminal B, HER-2, basal cell-like and 
normal breast-like, based on the expression of oestrogen receptor (ER), progesterone receptor 
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(PR), and the amplification of human epidermal growth factor receptor 2 (HER2/neu) (Figure 
2) [74].  
 
 
 
 
 
Figure 5. Histological and molecular subtypes of breast cancer. The anatomy of the breast (a) 
highlights the features implicated in the classification (lobule, duct, luminal epithelial cell, and basal 
myoepithelial cell). The tables (b) show different subtypes of breast carcinoma (Adapted from (Harbeck 
et al. 2019 [75]).  
  
1.6.2 Classification of breast cancer according to stage and tumour grade   
  
Identifying the stage of breast cancer and tumour grade is vital for prognosis and establishing 
effective treatment plans. Breast cancer is classified into five anatomic stages ranging from 
stage 0 to stage Ⅳ, according to the TNM staging system (Table 1), as reported by the 
American Joint Committee on Cancer (AJCC) [76]. The TNM system can be applied for most 
types of cancer and describes tumour size (T), lymph node involvement (N) and distant 
metastasis (M) [72]. Tumour grading classifies the tumours according to the degree of cell 
abnormality and differentiation as they appear under the microscope. In breast carcinoma the 
grades are as following; G1-low grade with relatively normal-appearing, well-differentiated 
cells, G2-moderate differentiation and G3-high grade, poorly differentiated with more 
abnormally appearing cells [77]. This grading serves as a prognostic tool in predicting how 
aggressively the tumour will grow and spread.  
13  
  
Table 1. Breast cancer staging according to the American Joint Committee on Cancer (AJCC)  
 
 TNM staging system   
Stage 0  Tis  N0  M0  
Stage Ⅰ A  T1  N0  M0  
Stage Ⅰ B  T0  N1mi  M0  
T1  N1mi  M0  
  
Stage Ⅱ A  
T0  N1  M0  
T1  N1  M0  
T2  N0  M0  
Stage Ⅱ B  T2  N1  M0  
T3  N0  M0  
   
Stage Ⅲ A  
T0  N2  M0  
T1  N2  M0  
T2  N2  M0  
T3  N1  M0  
T3  N2  M0  
  
Stage Ⅲ B  
T4  N0  M0  
T4  N1  M0  
T4  N2  M0  
Stage Ⅲ C  Any T  N3  M0  
Stage Ⅳ  Any T  Any N  M1  
  
T0 = no primary tumour, Tis = carcinoma in situ, T1 = Tumour ≤ 2cm, T2 = Tumour >2cm but 
≤5cm, T3 = Tumour >5cm, N0 = No regional lymph node metastases, N1mi = Micro- 
metastases, N1 = Metastases to movable ipsilateral level Ⅰ and/or level Ⅱ axillary lymph nodes, 
N2 = Metastases to fixed or matted ipsilateral level Ⅰ and/or level Ⅱ  axillary lymph nodes, N3 
= Metastases to ipsilateral level Ⅲ axillary lymph nodes with/out level Ⅰ, Ⅱ axillary lymph 
nodes involvement, M0 = absence of distant metastasis, M1 = Distant metastasis [76].  
14  
  
1.6.3 Types of breast cancer cell lines for in vitro studies   
  
Mechanistic studies on the efficacy of a new therapeutic intervention using molecules, 
pharmaceutical drugs, or plant-derived compounds in breast cancer and other diseases, 
routinely employ in vitro testing using specific cell lines as part of the evaluation strategy [78]. 
Breast cancer cell lines, such as the MCF- 7, have proven to be useful tools for these studies 
and can be classified according to their molecular subtype, as illustrated in Table 2.  
 Table 2. Molecular classification of breast cancer cell lines [79]  
Cell line  Classification  Hormonal profile  
MCF-7  Luminal A  ER+, PR+/-, HER2-  
BT474  Luminal B  ER+, PR+/-, HER2-  
MDA-MB-453  Luminal  ER-, PR-, HER2+  
SUM 190  Basal  ER-, PR-, HER2-  
MDA-MB-231  Basal B  ER-, PR-, HER2-  
HCC1569  Basal A  ER-, PR+/-, HER2+  
ER, (oestrogen receptor), PR, (progesterone receptor), HER2, (Human epidermal growth factor 
2) + (positive), - (negative)  
  
1.6.4 Breast cancer epidemiology   
   
According to WHO, breast cancer is the most common cancer in women, with 2.1 million new 
cases recorded in 2018 globally (approximately one new case per second) and an estimated 627 
000 deaths [80]. The incidence of breast cancer is estimated at about 1-in-8 women over a 
lifetime and is expected to increase steadily with human development [73]. Breast cancer 
incidence varies regionally across the world, with higher-income areas presenting higher rates 
viz. 92 per 100 000 in North America, and 27 per 100 000 in lower-income regions (Eastern 
Asia and Middle Africa). However, mortality is higher in low- and middle-income regions [81]. 
The difference in prevalence between population groups has been attributed to diet, age, genes, 
ethnicity, lifestyle, among other breast cancer risk factors, as well as the availability and access 
to resources for early detection [81].   
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1.7 Therapeutic approaches in cancer  
  
Generally, treatment approaches depend on the type and stage of cancer at the time of first 
discovery. Currently utilised methods of treatments comprise of surgery, radiotherapy, 
chemotherapy, hormone therapy, immunotherapy, gene therapy, targeted therapy among many 
others, used in combination or alone. However, the most commonly used treatments for cancer 
includes surgery, radiotherapy and chemotherapy [82]. Surgery involves the surgical removal 
of part or entire tumour mass from a body part and is mostly effective in localised primary 
tumours, either alone or in combination with radiotherapy or chemotherapy [83]. In breast 
cancer, breast-conserving surgery has become an established approach in early-stage breast 
cancer, which involves excision of the tumour (lumpectomy), as opposed to complete removal 
of the breast (mastectomy) [84]. Breast-conserving surgery is usually preceded or followed by 
some combination of chemotherapy, radiation or endocrine-therapy to reduce the tumour size 
as well as ensure minimal risk of metastases and full recovery [85, 86]. The disadvantages of 
surgery include inability to completely eradicate the peripheral parts of tumours and increased 
risk of induced acceleration of tumour and metastatic growth as a result of the inflammatory 
response to surgical trauma [87, 88].  
Radiotherapy is based on the use of high energy radiation to kill cancer cells by preventing cell 
division and proliferation through DNA damage [89]. Radiotherapy is commonly used in 
combination with surgery, administered after surgical tumour excision to reduce the risk of 
relapse [90]. Radiation sensitivity is inherently different for each tumour type, with lymphomas 
being the most sensitive, followed by breast and lung cancer as moderately sensitive, then 
osteosarcoma and melanoma with poor sensitivity [89]. The disadvantages of radiotherapy 
include non-selective killing of healthy cells in the peripheries of the tumour masses, limited 
therapeutic efficacy for distant metastases and progressive tumour radio-resistance [91].  
Chemotherapy is regarded as the most effective and widely used systemic treatment for most 
types of cancers [92]. Chemotherapy employs the use of cytostatic and cytotoxic 
chemotherapeutic drugs to kill cancer cells by inhibiting growth or halting cell progression and 
inducing apoptosis [92].  Numerous chemotherapeutic drugs have been explored in cancer 
treatment including platinum-based (cisplatin), anthracyline-based (doxorubicin, epirubicin 
and daunorubicin) and paclitaxel-based (Taxol® and Abraxane®) chemotherapies, and 
combination chemotherapies such as doxorubicin and cyclophosphamide followed by 
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paclitaxel used in breast cancer therapy [88, 93, 94]. However, due to non-specificity, 
chemotherapeutic drugs target both cancer cells and healthy cells resulting in numerous adverse 
side effects such as anaemia, nausea, vomiting and hair loss [95]. Therefore, there remains a 
need to identify new therapeutic approaches with minimal side effects and enhanced target 
specificity. Plant-derived drugs have recently gained recognition as alternative cancer treatment 
options with minimal side effects [24]. An important strategy is the use of nanotechnology in 
drug development, which offers delivery systems with improved bioavailability and target 
specificity. Hence, the evaluation of plant-derived compounds using nanotechnology could 
offer promising alternative treatment options for cancer.   
  
1.7.1 The therapeutic use of medicinal plants and plant-derived compounds in cancer  
  
The increasing development of resistance to treatment, coupled with nonspecific toxicity of 
traditional chemotherapies poses significant drawbacks in cancer treatment [96]. In light of 
this, plant-derived compounds have attracted considerable interest as chemotherapeutic and 
chemopreventive agents in cancer treatment [78]. Plant-derived compounds are typically 
perceived as non-toxic to healthy cells and are a source of novel molecules for drug discovery 
[24]. For centuries, plants have been utilized by humanity as medicines and therapies for 
numerous diseases including cancer, with approximately 60% of current cancer treatments 
being derived from natural sources [3]. In China, traditional herbal medicine is widely accepted 
as a form of alternative treatment for cancer and over 400 herbal variants have been registered 
in the Chinese Herbal registry for cancer therapeutic use [82, 97]. In Africa, where the 
affordability of modern cancer medicine is a key factor, many cancer patients still rely on 
readily available plant-derived drugs for their healthcare [98]. Notably, a significant number of 
new anticancer agents originating from African plants have been tested in clinical trials, for 
example; curcumin isolated from Curcuma longa L (turmeric commonly found in Asia and 
Africa) and perillyl alcohol isolated from Lavandula X intermedia essential oils, which is 
widely distributed in South and North Africa [99].  
Plant-derived compounds have been shown to exhibit potent anti-proliferative and proapoptotic 
properties against various types of cancers and modulate multiple signalling pathways [100]. 
Examples include curcumin, a polyphenolic compound, shown to inhibit tumour progression 
and metastasis in various cancers through suppressing the expression of transcription factor 
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NF-KB [101]. Moreover, phase Ⅱ clinical trials of curcumin in pancreatic cancer patients 
demonstrated significant tumour regression with no toxic effects [99].  
Quercetin, a flavonoid, was shown to inhibit proliferation of lung, colon, prostate and breast 
cancer cells, and induce apoptosis and cell cycle arrest through modulating various pathways 
[8]. Berberine, an alkaloid, was shown to effect cell cycle arrest at different phases in tumour 
cells through upregulation of miR-23a, which induces overexpression of cell cycle regulating 
proteins such as CIP1/p21 and Kip1/p27 and downregulates expression of cyclin-dependent 
kinases [102]. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, was shown to 
promote apoptosis through increasing the Bax/Bcl-2 ratio, inhibiting the activation of NF-KB 
and activating caspases [103]. Among cancer therapeutics, two classes of plant-derived 
compounds, alkaloids and polyphenols are predominant [6]. In this study, we focus on one class 
of polyphenols identified as flavonoids.     
  
1.7.2 Flavonoids: Classification, structure and therapeutic use in cancer  
  
1.7. 2.1 Classification  
  
Flavonoids constitute the largest group of polyphenolics and are characterised by a C6-C3-C6 
basic carbon skeleton [104]. They naturally occur in a variety of plants and are correlated with 
a plethora of health benefits and low systemic toxicity. Structurally, flavonoids are divided into 
various classes including flavones, flavanones, flavanols, flavonols, anthocyanidins and 
isoflavonoids (Figure 6) [5].  
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Figure 6. Classification of flavonoids. Classification of flavonoids into six groups; flavone, flavonol, 
flavanone, flavonol, anthocyanidin and isoflavonoid, based on differences in the molecular structure 
from the basic flavonoid skeleton, see review by Abotaleb et al. 2019 [5].  
  
1.7.2.2 Structure  
  
The structural variations of flavonoids have been reported to influence their biological 
activities. These distinctive variations are usually observed in the C-ring, with the presence or 
absence of a double bond at position 2, OH substitution at position 3 and/or carbonyl at position 
4. In the A and B rings, differences occur in the number and position of -OH or -OCH3 
substitutions; and the presence of glycol moiety usually in the A ring [104]. Previous studies 
comparing the cytotoxic effects of 23 structurally different flavonoids in MCF-7, MDA-
MB231, and prostate cancer cell lines, demonstrated that the presence of 2,3 double bond 
enhanced cytotoxicity [105]. Flavones, with B-ring hydroxyl group substitution and a double 
bond in the C-ring, proved to be potent proteasome inhibitors and inducers of apoptosis in 
tumour cells [106]. Furthermore, methoxylation in the A-ring showed strong antiproliferative 
activity in cancer cells treated with the flavonoids, nobiletin and sinensetin [107].  
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1.7.2.3 Therapeutic use in cancer  
  
A growing number of epidemiological studies indicate that a high intake of dietary flavonoids 
is correlated with lower incidence of various cancers, including breast cancer [108]. Several in 
vitro and in vivo studies have demonstrated the ability of flavonoids to inhibit cell proliferation, 
invasion and metastasis, and promote cell cycle arrest and apoptosis, and modulate molecular 
events in carcinogenesis [109]. As discussed before, cancer cells may become resistant to 
chemotherapeutic treatment, resulting in tumour propagation and metastasis. Flavonoids have 
been shown to halt the propagation of resistant cells by promoting cell death or re-sensitising 
the cancer cells to chemotherapeutic treatments [110].   
Flavones possessing a 2,3 double bond and hydroxyl groups, such as apigenin and luteolin, 
found in spinach and aromatic flowering plants, respectively, have shown anticancer activity 
in human breast, prostate and colorectal cancer [5, 110]. With luteolin and apigenin, inhibition 
of PI3K/Akt and activation of the fork-head box protein, resulted in the induction of apoptosis 
and cell cycle arrest in MCF-7 and TNBC cells [108]. Luteolin was shown to exhibit apoptotic 
efficacy in MCF-7 through activation of the caspase cascade, PARP inactivation, cytochrome 
c release, and inhibition of Bcl-2 expression [111]. Combination treatment of apigenin and 
cisplatin enhanced cytotoxic and apoptotic effects in MCF-7 through modulation of tumour 
suppressor p53 [112],  and in prostate cancer stem cells through downregulating anti-apoptotic 
Bcl-2, survivin and sharpin expression, and upregulating pro-apoptotic caspase-8 and p53 
expression [113]. Through blockage of the signal transducer and activator of transcription 3, 
apigenin reversed drug resistance in adriamycin-resistant breast cancer cells (MCF-7/ADR) 
[114].  
Flavanones, characterised by the absence of a double bond at position 2 in the C-ring, include 
hesperidin, aglycone hesperetin and naringenin, which are abundantly distributed in citrus fruits 
[115]. Hesperetin and naringenin are the most studied citrus flavonoids while studies on 
hesperidin are minimal. Hesperetin exerted pro-apoptotic effects in MDA-MB-231 and MCF7 
cells through the intrinsic mitochondrial pathway [5]. Hesperidin was shown to induce 
phosphatidyl-serine externalisation, activation of caspases, the release of cytochrome c, 
collapse of mitochondrial membrane potential, and increases Bax: Bcl-2 ratio to promote 
proapoptotic effects in breast cancer cells [116]. Hesperidin was also found to reduce cell 
proliferation and promote G2/M phase cell cycle arrest in gallbladder cancer cells [117]. 
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Naringenin exhibited antiproliferative effects through modulation of Bcl-2 family genes, 
activation of caspases, cell cycle arrest in G0/G1 phase, activation of extrinsic and intrinsic 
apoptotic pathways, impairment of glucose uptake and induction of mitochondrial dysfunction 
in a wide range of human cancer cells including breast cancer [115].   
Naturally occurring flavonoids have proven to be potent agents in cancer treatment and 
prevention, however, owing to their varying bioavailability and poor systemic delivery, their 
success in clinical use is affected and limited [108]. Therefore, there is an urgent need to explore 
different options to improve their bioavailability and develop effective drug delivery systems.  
  
1.7.3 Nanoencapsulated plant-derived compounds in cancer therapeutic strategies  
  
Nanoencapsulation can offer an attractive alternative approach for improving putative 
therapeutic properties of plant-derived compounds such as bioavailability, stability, and site-
specific targeted and controlled delivery in cancer. Nanoencapsulation is a technique that 
encompasses encapsulating or entrapping bioactive compounds into a nanoscale carrier or 
system of a size range of 1-1000 nm [118]. The nanocarrier preserves the bioactive compound 
from premature gastrointestinal degradation, improves therapeutic efficacy, solubility, and 
bioavailability of the bioactive compound due to the increased surface area per unit volume, 
and increases compound accumulation into the target cancer cell [119]. Furthermore, 
nanocarriers can be fine-tuned for optimised therapeutic effect through adjusting their size and 
shape, alternating their chemical composition and modifying their surface properties such as 
surface charge, surface coating or PEGylation, and attaching functional groups or targeting 
moieties [120].   
Various nanocarriers such as nanoemulsions, solid lipid nanocarriers, liposomes, polymeric 
micelles dendrimers, and many others have been developed and are currently being optimised 
for improved drug delivery systems. Lack of site-specific delivery is among the major 
drawbacks of current chemotherapies and clinically used anti-cancer compounds [3]. 
Nanoencapsulation enables preferential accumulation of the active drug at the diseased site 
through passive or active targeting. In vitro drug delivery into the intracellular target site can 
be achieved through endocytosis (internalisation through engulfment). Endocytosis can be 
activated through selective binding of ligands, attached on the nanosystems, onto the cell 
surface receptors or through non-selective binding based on electrostatic interactions [121].  In 
21  
  
vivo, the tumour vasculature is characterised by an irregular structural network with immature, 
tortuous, leaky and hyperpermeable vessels [122]. In addition to the aberrant vessels, tumours 
also have acidic microenvironments (low pH in comparison to healthy cells) and lack lymphatic 
drainage [123]. This unique morphology of solid tumours allows for passive drug delivery 
(Figure 7). Depending on the tumour type, the tumour endothelial cell lining gaps can be 
enlarged up to 70 times more than normal endothelium (700 nm tumour endothelium vs. 10 nm 
normal endothelium) [120]. Hence, drugs delivered in nano-systems due to their size and the 
leaky vasculature, and lack of lymphatic drainage can selectively accumulate and be retained 
in the tumour site through the enhanced permeability and retention effect (EPR) [124].   
The acidic pH (range 6.5 - 6.8) of the solid tumours is also exploited for passive delivery of 
drugs by the use of nano-systems with acidic pH-responsive transition as part of their 
physicochemical properties [123]. Likewise, surface coating of nanocarriers with poly 
(ethylene glycol) PEG enhances stealth properties, prolongs systemic circulation time, and 
enhances the accumulation of encapsulated drugs to the tumour site through passive targeting 
[125]. Active targeting involves affinity-based recognition of receptors on the target cell 
surface by biological ligands conjugated to the drug-loaded nanosystems, resulting in selective 
drug accumulation at the tumour site [126]. Receptors overexpressed on cancer cell surfaces 
include HER2, epidermal growth factor receptor (EGFR), folate, integrins, and transferrin.  
Moieties used as target ligands include proteins, carbohydrates, monoclonal antibodies, 
vitamins and peptides [127].   
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Figure 7. Schematic representation of (a) passive and (b) active targeting for drug delivery in solid 
tumours. In passive targeting nanoparticles selectively accumulate at the tumour site through the 
enhanced permeability and retention effect (EPR). However, in active targeting, nanoparticles exploit 
both the EPR effect and selective binding of the active ligands conjugated to their surface to 
overexpressed receptors on the tumour cell surface (Upponi & Torchilin 2014 [128]).   
Incorporation of plant-derived compounds into nanocarriers have shown great potential in 
improving their efficacy in cancer treatment. For example, the encapsulation of 
epigallocatechin-3-gallate (EGCG), a green tea derived polyphenol, into polymeric 
nanosystems resulted in ten-fold drug-dose advantage in exerting pro-apoptotic and 
antiangiogenic effects against prostate cancer in contrast to free EGCG [129].  Quercetin-
loaded solid lipid nanoparticles demonstrated an increased apoptotic index in comparison to 
free quercetin in MCF-7 breast cancer cells [130]. Similarly, kaempferol-loaded mucoadhesive 
nanoemulsions exhibited decreased cell viability in contrast to free kaempferol, and induced 
apoptosis in glioma cells [131]. Together, this evidence shows the potential of nanosystems to 
circumvent the drawbacks of using unmodified bioactive compounds and existing 
chemotherapeutics in cancer treatment.  
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1.8 Eriocephalus africanus   
  
Eriocephalus africanus is an evergreen, aromatic, indigenous plant widely distributed in the 
south-western Cape region of South Africa. E. africanus is commonly known as ‘wild 
rosemary,’ owing to its leaf morphology (Figure 8) being similar to that of culinary rosemary 
(Rosmarinus officinalis L); however, it is a member of the Asteraceae family and genus 
Eriocephalus [132].  
   
 
Figure 8. Eriocephalus africanus, of the family Asteraceae, commonly known as ‘wild rosemary,’ (a) 
shows the aerial view of wild rosemary and (b) close-up morphology of the plant [132].  
  
1.8.1 Traditional use, biological activity and phytochemical constituents  
  
Traditionally, E. africanus is used to treat dermal diseases, heart conditions and inflammation. 
Infusions of this plant are used in herbal remedies such as diuretics and the treatment of 
gastrointestinal disorders, as well as coughs and fever [133]. However, despite its acclaimed 
ethnomedicinal uses, only a few scientific studies report on its antioxidant [134] and 
antibacterial properties [135]. Currently, there are no reports on the anticancer properties of E. 
africanus, although several plants from its family (Asteraceae) have been reported to possess 
anti-carcinogenic abilities [136]. The phytochemical constituents of the Asteraceae family 
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include polyphenols, alkaloids and terpenes including sesquiterpene, possessing numerous 
disease curative and preventive properties [137].  
  
1.9 Problem statement  
  
Cancer, including breast cancer, continues to be one of the leading causes of death worldwide. 
Despite the considerable advances made in the treatment of cancer over the past two decades, 
existing therapies have demonstrated several drawbacks, including low bioavailability, adverse 
side effects, non-selective toxicity to healthy cells, development of chemoresistance and lack 
of target specificity, in some cases. In light of these drawbacks, the development of alternative 
efficient therapeutics with minimal toxicity is needed in the treatment of cancer. Plant-derived 
molecules are emerging as potential alternative treatment options with typically low toxicity. 
Moreover, the incorporation of phytochemicals into novel nano-drug systems is showing 
significant enhancement in their efficacy, bioavailability and target specificity. It is within this 
context that this study was conducted, to investigate the potential of Eriocephalus africanus, a 
medicinal plant, with little scientific validation despite belonging to a family (Asteraceae) with 
well recognised anticarcinogenic abilities.   
  
1.10 Aim  
  
The aim of this study was to isolate and characterise phytocompounds from Eriocephalus 
africanus L., investigate their effects on cytotoxicity, cell cycle progression, apoptotic and 
epigenetic control in breast cancer using human breast adenocarcinoma cell lines (MCF-7) and 
develop nanosystems for their encapsulation, which were evaluated for safety and efficacy as 
anticancer agents against MCF-7.  
  
Objectives  
• To isolate, characterise and identify the secondary metabolites from the methanolic 
extract of E. africanus using column chromatography and spectroscopic techniques (IR, 
MS and NMR)  
• To screen for potential anticancer activity of the isolated compounds via the MTT assay  
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• To determine the cytotoxicity of the selected compounds against MCF-7 at varying 
concentrations and duration via the MTT assay  
• To evaluate the apoptotic activity and effect on cell cycle progression of the selected 
compounds using flow cytometric techniques  
• To determine the effect of the phytocompounds on expression of key apoptotic mRNA 
and miRNA using quantitative Real-Time PCR  
• To synthesise lipid-based nanosystems for the selected phytocompounds  
• To evaluate the physicochemical properties of the synthesised nanosystems in terms of 
surface morphology, polydispersity index (PDI), zeta potential (ZP), encapsulation 
efficiency and in vitro drug release  
• To determine the safety of the synthesised nanosystems through in vitro cytotoxicity 
against non-cancerous human embryonic kidney cells (HEK 293) and haemolytic 
studies  
• To evaluate their efficacy and anticancer therapeutic potential in breast cancer using 
MCF-7 cell lines  
  
1.11 Novelty of the study  
  
This study is among the first in providing a scientific basis for the medicinal properties of E. 
africanus. It demonstrates the potential of the plant as a source of flavonoids as well as the 
potential of plant-derived flavonoids and flavonoid-loaded nanosystems for the development 
of alternative treatments targeting the apoptotic pathway in breast cancer.   
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1.12 Thesis overview  
  
The research findings of this study are presented in this thesis in the form of research 
manuscripts:  
 
Chapter one: Provides the introduction with a brief background to the study and a literature 
review focusing on topics relevant to the study. The problem statement, aim and objectives are 
also outlined in this chapter.  
  
Chapter two: Manuscript one - Highlights the isolation of phytochemicals from the 
methanolic extract of E. africanus, the spectroscopic characterisation of the isolated 
compounds and the preliminary screening for their anticancer activity. This chapter is a first-
authored experimental article published in the ISI accredited journal, Natural Product Research.  
  
Chapter three:  Manuscript two - Reports the effects of isolated flavonoids on the apoptotic 
and cell cycle machinery in MCF-7, and their effect on expression of key apoptotic miRNA. 
This study is a first-authored experimental article currently under revision by the ISI accredited 
Journal of Biomolecular Structure and Dynamics (corrections submitted).  
  
Chapter four: Manuscript three - Details the synthesis of novel hesperidin-loaded 
nanoemulsions (HP-NEM), presents the physicochemical properties of HP-NEM, safety 
evaluations and highlights the potential of HP-NEM as cytotoxic agents and inhibitors of 
oncomirs miR-21 and miR-155 expression in breast cancer cell lines. This study is a first-
authored experimental article under review in the ISI accredited Journal of Drug Targeting.  
  
Chapter five: Provides the synthesis and overall conclusions of the research findings from this 
study. Recommendations for further research are also summarised.  
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 2.  CHAPTER TWO: MANUSCRIPT ONE  
  
2.1 Phytochemical constituents and in vitro anticancer screening of isolated compounds from 
Eriocephalus africanus  
  
Published in: Natural Product Research, DOI: 10.1080/14786419.2020.1744138 To 
link to this article: https://doi.org/10.1080/14786419.2020.1744138  
  
In the search for new, safe and alternative plant-derived therapeutics for the treatment and 
management of cancer, the study in this chapter explores the anticancer potential of the plant 
species, Eriocephalus africanus, belonging to the family Asteraceae. Literature demonstrated 
Asteraceae to possess numerous phytocompounds with anticancer activities; however, there are 
no scientific reports on the anticancer activity of this species, despite belonging to the same 
family. Therefore, this chapter presents a detailed investigation on the phytochemical 
constituents of E. africanus from extraction, isolation, characterisation and identification, and 
in vitro screening for anticancer potential of the extracts and isolated phytocompounds.  
This chapter is formatted according to the journal specifications.  
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Phytochemical constituents and in vitro anticancer screening of isolated 
compounds from Eriocephalus africanus   
Judie Maguraa, Roshila Moodleyb*, Kaminee Maduraya and Irene Mackraja  
aSchool of Laboratory Medicine and Medical Sciences, University of KwaZulu–Natal, 
Durban, South Africa bSchool of Chemistry and Physics, University of KwaZulu–Natal, 
Durban, South Africa  
Abstract  
This study investigated the in vitro anticancer potential of phytochemical constituents isolated 
from the methanolic extract of Eriocephalus africanus. One flavanone (hesperidin) and two 
flavones (luteolin and apigenin) were isolated for the first time from the plant using column 
chromatography. Standard MTT assay was used to evaluate the effect of the constituents on 
cell viability in MCF-7, A549, HepG2 and normal HEK 293 cell lines. The flavonoids 
decreased cell viability in a dose-dependent manner in all tested cell lines. Hesperidin and 
luteolin were more sensitive against MCF-7, with EC50 values of 62.57 µg/mL and 70.34 
µg/mL, respectively and apigenin showed the most potent activity against HepG2 (EC50 = 
11.93 µg/mL). The results revealed E. africanus to be a rich source of flavonoids and natural   
anticancer agents, which could potentially be used in the development of new therapeutics for 
cancer treatment.   
Graphical Abstract 
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1. Introduction  
Plant-derived ‘natural’ compounds have made a significant impact on modern medicine as a 
source for novel drug development. Currently, natural products and their derivatives account 
for more than half of the Food and Drug Administration (FDA) approved anticancer drugs (Sofi 
and Nabi 2018). These anticancer agents have reduced cell toxicity, minimized side effects and 
improved treatment efficacy compared to conventional methods of treatment, which include 
surgery, radiation, and chemotherapy (Rayan et al. 2017). Drugs of natural origin in clinical 
use for the treatment of various cancers include paclitaxel derived from Taxus brevifolia L. 
(pacific yew tree), Vincristine derived from Catharanthus roseus (L.) G. Don. (periwinkle) and 
epigallacotechin-3-gallate, a phenolic catechin from green tea (Cragg and Pezzuto 2016). The 
plant kingdom hosts a wide and diverse variety of compounds that have shown to exert 
anticancer activities by inducing apoptosis or autophagy, inhibiting tumour angiogenesis, and 
enhancing antioxidant activity (Wang et al. 2012).   
Eriocephalus africanus is commonly known as ‘wild rosemary’, derived from its leaf 
morphology, which is similar in appearance to that of rosemary (Rosmarinus officinalis L.); 
however, it is from the family Asteraceae (Merle et al. 2007). Traditionally, it is used to treat 
heart disease, inflammation and dermal conditions. A few studies have reported E. africanus to 
have antioxidant and antibacterial activities (Mohamed et al. 2017; Behiry et al. 2019). 
However, despite these preliminary reports and its use in ethnomedicine, there is still a lack of 
scientific knowledge regarding its chemical constituents and biological activities. This study, 
therefore, aims to isolate the major secondary metabolites from E. africanus and screen for their 
anticancer potential (in vitro) against human carcinomas namely, breast cancer (MCF-7), lung 
cancer (A549) and liver cancer (HepG2).  
  
2. Results and Discussion  
2.1 Characterisation of isolated compounds  
The isolated compounds were identified based on spectral data (Supplementary material, 
Figures S1-S21) and by comparison to literature (Lahmer et al. 2015; Mohamed et al. 2015;  
Jadeja et al. 2017). Compound 1 identified as hesperidin (Supplementary material, Figure S22);  
HR-ESI-MS m/z 609.18 [M-H] +corresponding to C28H34O15. Compound 2, luteolin 
(Supplementary material, Figure S22) was obtained as a yellow powder; HR-ESI-MS m/z 
42  
  
285.04 [M-H] + corresponds to C15H10O6. Compound 3 was identified as apigenin 
(Supplementary material, Figure S22), HR-ESI-MS m/z 269.04 [M-H] + corresponds to  
C15H10O5.   
2.2 Anticancer activity  
The in vitro anticancer activity screening via the MTT assay showed that the ethyl acetate 
fraction (EtOAc) of MeOH extract prepared from E. africanus and their isolated compounds 
reduced significantly cell viability in a dose-dependent manner, with moderate cytotoxicity 
against the normal human embryonic kidney cell line (HEK 293) (Supplementary material, 
Figure S23(a)-(d)). Hesperidin and luteolin were more sensitive against MCF-7 (EC50 of 62.57 
µg/mL and 70.34 µg/mL, respectively) than HepG2 and A549. Moreover, the EtOAc showed 
the highest effect against MCF-7 with EC50 of 45.47 µg/mL proving the synergistic effect of 
the compounds. Apigenin showed the strongest anticancer effects against HepG2 (EC50 of 
11.93 µg/mL) and reduced cell viability to at least 23% against A549 at higher concentrations 
(200 µg/mL). Previously, anticancer activity of natural flavonoids including apigenin, against 
human carcinomas, have been reported (Yan et al. 2017), and these have been consistent with 
this study for apigenin against HepG2.   
The activity of flavonoids has been proposed to be partly linked to their structure, which 
consists of two benzene rings (A and B) linked by a 3-carbon heterocyclic ring (C). Previous 
studies have demonstrated the influence of substitution on the B-ring on the function of 
flavonoids as ERβ (estrogen receptor β) agonists, where the absence of substitution increased 
potency while substitution reduced potency (Huang et al. 2010). In another study by Krych and 
Gebicka (2013), it was observed that OH- substitution on the B-ring at position 4′ and 5′ 
enhanced the inhibitory activity of catalase enzymes (enzymes belonging to the antioxidant 
defence system of a cell) whereas, substitution on the B-ring at position 3′ decreased the 
activity. In our study, although not all the activity can be fully attributed to positional structure, 
significant differences in activity between hesperidin (with position 3′ substitution) and 
apigenin (without position 3′ substitution) were observed. Further investigation is required to 
conclusively investigate the effect of structure on anticancer activity in flavonoids. The 
anticancer activity of hesperidin, luteolin and apigenin has previously also been attributed to 
induction of DNA fragmentation, promotion of caspase-3 and 9 cleavage, and cell cycle arrest 
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at the G2/M phase through elevated levels of reactive oxygen species, respectively (Abotaleb 
et al. 2019).  
  
3. Conclusion   
This study revealed, for the first time, that the methanol extract of E. africanus was a rich source 
of natural flavonoids which could be potential anticancer agents, as they exhibited a significant 
reduction in cell viability for all the tested cancer cell lines. Furthermore, apigenin isolated 
from E. africanus produced remarkable anticancer activity against HepG2 which suggests its 
possible use in the development of new therapeutics against liver cancer.   
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SUPPLEMENTARY MATERIAL   
Phytochemical constituents and in vitro anticancer screening of isolated 
compounds from Eriocephalus africanus   
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Abstract  
This study investigated the in vitro anticancer potential of phytochemical constituents isolated 
from the methanolic extract of Eriocephalus africanus. One flavanone (hesperidin) and two 
flavones (luteolin and apigenin) were isolated for the first time from the plant using column 
chromatography. Standard MTT assay was used to evaluate the effect of the constituents on 
cell viability in MCF-7, A549, HepG2 and normal HEK 293 cell lines. The flavonoids 
decreased cell viability in a dose-dependent manner in all tested cell lines. Hesperidin and 
luteolin were more sensitive against MCF-7, with EC50 values of 62.57 µg/mL and 70.34 
µg/mL, respectively and apigenin showed the most potent activity against HepG2 (EC50 = 
11.93 µg/mL). The results revealed E. africanus to be a rich source of flavonoids and natural 
anticancer agents, which could potentially be used in the development of new therapeutics for 
cancer treatment.   
  
Keywords: Flavonoids; apigenin; hesperidin; luteolin; HepG2; natural products.  
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Experimental   
General procedures  
Infrared (IR) spectra were recorded on a Perkin Elmer Spectrum 100 FT-IR spectrometer 
accessorized with a universal attenuated total reflectance (ATR). Nuclear magnetic resonance 
(NMR) spectra (1H, 13C and 2D) were recorded in deuterated DMSO (Merck, Darmstadt, 
Germany) at room temperature on a 600 MHz spectrometer (AVANCE III, Bruker, 
Rheinstetten, Germany). High resolution mass spectra (HR-MS) were recorded using a timeof-
flight mass spectrometer (LCT Premier TOF-MS, Waters Micro-mass, Milford, MA, USA). 
Column chromatography was performed using silica gel (Kieselgel 60, 0.063-0.200 mm, 
Merck, Darmstadt, Germany) and Sephadex LH-20 (25-100 µm bead size, Sigma-Aldrich, 
Germany). Thin layer chromatography (TLC) was carried out on TLC plates (Merck silica gel 
60, 20× 20 cm F254 aluminum sheets), which were developed in 10% H2SO4 in methanol 
(MeOH) and viewed under an ultraviolet lamp (254 nm).  Cells for seeding were counted using 
the Countess II FL automated cell counter (Thermofisher, Waltham, MA USA). All reagents 
including 3-(4,5-dimethylthiazolyl)-2,5-diphenyl-tetrazolium bromide (MTT), 2,2-diphenyl-
1picrylhydrazyl (DPPH) and 5-fluorouracil (5FU) were of analytical grade and they were 
purchased from Sigma-Aldrich, Germany.  
Plant material  
Plant material was collected from St Thomas` Anglican Musgrave, Durban (Latitude 
29.846514, Longitude 31.000609) during summer and was identified as Eriocephalus 
africanus by the botanist, Sandra Dell from Botanical Society of South Africa - KZN Coastal 
Branch. A voucher specimen (No. Magura 01) was deposited in the ward herbarium at UKZN. 
The collected aerial parts of the plant (leaves and stems) were initially washed using tap water 
then double-distilled water and allowed to air dry (during summer temperatures range from 27 
o C to 32 o C). The dried sample was crushed into powder form using a home blender (Braun 
JB 5160, Kronberg im Taunus, Germany).  
Preparation of the ethyl acetate from MeOH (EtOAc) extract  
The dry powdered sample (1.8 kg) was successively extracted with MeOH (3 × 2500 mL) at 
25 o C for 72 h using an orbital shaker and evaporated using a rotary evaporator at 65 o C to 
obtain a crude extract. The crude extract (approximately 100 mL) was dissolved in water (300 
mL) and partitioned twice with an equal volume of 100 mL of ethyl acetate (EtOAc). The 
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obtained EtOAc fraction from the MeOH extract was evaporated to dryness using a rotary 
evaporator to yield 10 g then subjected to preliminary bioactivity screening via antioxidant 
assays, Figure S24.   
Antioxidant activity of the ethyl acetate fraction from the methanol extract  
Three assays were used to evaluate the antioxidant activity namely, DPPH radical scavenging 
activity, reducing power activity, and nitric oxide radical scavenging activity. The EtOAc 
fraction from the MeOH extract showed strong antioxidant activity (Figure S24) and was then 
subjected to column chromatography for the isolation of compounds. The isolated compounds 
were characterised using NMR, IR and HR-MS.   
Isolation of phytocompounds   
Guided by the antioxidant screening, the EtOAc fraction from the MeOH extract (4 g) was 
redissolved in MeOH and filtered using a Whatman No 8-filter paper; the residue gave 
compound 1 (200 mg). The filtrate was subjected to column chromatography using silica gel 
(Merck Kieselgel 60, 0.063-0.200 mm, 70-230 mesh ASTM) as the stationary phase and 
EtOAc: MeOH (10:0, 9:1, 8:2 and 7:3, v/v) as the mobile phase. Thereafter, Sephadex LH-20 
was used, and elution was effected with 100% MeOH. TLC was used to monitor collected 
fractions and those with similar profiles were combined and recrystallised. The Sephadex 
column afforded compound 2 (60 mg). Compound 3 (36 mg) was obtained from fractions (21-
23) eluted from the silica gel column.  
Compound 1, Figure S1-S7:   
1H-NMR (600 MHz, DMSO, δH ppm), 
1H-NMR (600 MHz, DMSO, δ ppm), 11.96 (s, 1H, 
5OH), 6.93 (d, J = 4.20 Hz, 1H, H-2'), 6.90 (dd, J = 8.60, 4.20 Hz, 1H, H-6'), 6.89 (d, J = 8.60  
Hz 1H, H-5'), 6.13(d, J = 2.41 Hz, 1H, H-8), 6.12 (s, 1H, H-6), 5.49 (dd, J = 8.60, 3.15 Hz,1H,  
H-2), 4.94 (d, J = 7.72 Hz, 1H, H-1''), 4.52 (d, J = 1.79 Hz, 1H, H-1'''), 3.80 (s, 3H, -OCH3),   
3.20–3.60 (6H, m, H-2'' to H-6''), 3.20–3.60 (3H, m, H-2''' to H-6'''), 3.31 (dd, J = 17.23, 8.52 
Hz 1H, H-3a), 2.78 (dd, J =17.16, 3.00 Hz,1H,  H-3b), 1.08 (d, J = 6.0 Hz, 3H, H-6''').   
13C NMR (600 MHz, DMSO- δC ppm): 197.41 (C-4), 165.52 (C-7), 163.41 (C-5), 162.8 9 (C9), 
148.43 (C-4'), 146.80 (C-3'), 131.23(C-1'), 118.52(C-6'), 114.48 (C-2'), 112.51 (C-5'),  
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103.81(C-10), 100.90 (C-1'''), 99.89 (C-1''), 96.88 (C-6), 96.06 (C-8), 78.78 (C-2), 76.61 (C5''), 
75.91 (C-2''), 73.38 (C-4'''), 72.32 (C-3''), 71.10 (C-4''), 70.66 ( C-3'''), 70.06 (C-2'''), 68.72 (C-
5'''), 66.39 (C-6''), 56.16 (-OCH3), 42.36 (C-3), 18.14 (-CH3).   
Compound 2, Figure S8-S14:   
1H-NMR (600 MHz, DMSO, δH ppm), 12.97 (s, 1 H, 5-OH), 7.42 (d, J = 2.33 Hz, 1H, H-2'), 
7.41(dd, J = 9.01, 2.33 Hz, 1H, H-6') 6.91 (d, J = 8.72 Hz, 1 H, H-5'), 6.67 (s, 1 H, H-3), 6.46 
(d, J = 2.21 Hz, 1H, H-8), 6.20 (d, J = 2.25 Hz, 1H, H-6).    
13C NMR (600 MHz, DMSO- δC ppm): 182.09 (C-4), 164.99 (C-7), 164.35 (C-2), 161.88  
(C-5), 157.78 (C-9), 150.38 (C-4'), 146.29 (C-3'), 121.81 (C-1'), 119.42 (C-2'), 116.53 (C-5'), 
113.77 (C-6'), 103.99(C-10), 103.20(C-3), 99.40 (C-6), 94.41(C-8).   
Compound 3, Figure S15-S21:  
 1H-NMR (600 MHz, DMSO, δH ppm ), 12.87 (s, 1 H, 5-OH), 7.89 (d, J = 8.00 Hz, 2H, H-2', 
6'), 6.94 (d, J = 8.80 Hz, 2H, H-3', 5'), 6.69 (d, J =  2.37 Hz,1H, H-6), 6.47 (d, J = 1.85 Hz, 1H, 
H-8), 6.17 (s, 1H, H-3).  
13C NMR (600 MHz, DMSO- δC ppm): 182.11 (C-4), 165.28 (C-7), 164.28 (C-2),161.74 (C5), 
161.15 (C-4'), 157.86  (C-9), 128.92  (C-2', 6'), 121.63 (C-1'), 116.53 (C-3', 5'), 103.84 (C-10), 
103.14 (C-6); 99.55 (C-3), 94.67 (C-8).  
Anticancer activity or cytotoxicity screening  
Human MCF 7, A549, HepG2 and HEK 293, originally procured from the American Tissue 
Culture Collection (ATCC) (Virginia, USA) were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM, Biowest, USA) supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin or streptomycin at 37 o C and 5% CO2. For the MTT assay, cells were seeded in 
96well microtiter plates at 5 × 103 cells/well in 100 µL of supplemented DMEM and incubated 
(37 o C, 5% CO2), for 16 h. The medium was removed and the test compounds, prepared by 
dissolving in DMSO and diluting with supplemented media to give concentration ranges of 
20200 µg/mL, were added to each well (100 µL final volume). The final concentration of 
DMSO in each well was less than 0.5%. The wells receiving only medium served as the blank, 
untreated cells in supplemented DMEM as the negative control and 5-FU was used as a positive 
control. After 24 h of incubation with the test compounds, the medium was removed and 100 
µL of fresh medium was added, followed by 20 µL of MTT (5mg/mL in PBS). The plates were 
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incubated for 4 h. Thereafter, the purple formazan crystals that formed were dissolved by 
adding 100 µL of DMSO to each well. The absorbance was measured at 560 nm using a 
microplate reader (SPECTROstar Nano, BMG Germany). All experiments were done in 
triplicate and repeated at least once for reproducibility.  
Statistical analysis  
Statistical analysis was carried out using the ANOVA test and the significant difference 
between means was tested by Tukey`s post hoc at p < 0.05. Measurements were conducted in 
triplicate and expressed as mean ± SD. The Statistical Package for the Social Sciences (PASW 
Statistics 24, IBM Corporation, Cornell, N.Y.) was used.  The EC50 values were calculated 
using the non-linear regression dose versus response curves (GraphPad Software, La Jolla CA).   
Spectral data for hesperidin, luteolin and apigenin  
  
Figure S1. 1H-NMR spectrum for hesperidin (1)  
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 Figure S2. 13C-NMR spectrum for hesperidin (1)  
 
  
Figure S3. DEPT spectrum for hesperidin (1)  
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Figure S4. HSQC spectrum for hesperidin (1)  
  
 
  
Figure S5. HMBC spectrum for hesperidin (1)  
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Figure S6. Mass spectrum for hesperidin (1)  
  
  
  
  
  
Figure S7. IR spectrum for hesperidin (1)  
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Figure S8. 1H-NMR spectrum for luteolin (2)  
 
  
Figure S9. 13C-NMR spectrum for luteolin (2)  
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Figure S10. DEPT spectrum for luteolin (2)  
  
  
  
Figure S11. HSQC spectrum for luteolin (2)  
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Figure S12. HMBC spectrum for luteolin (2)  
  
  
Figure S13. Mass spectrum for luteolin (2)  
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Figure S14. IR spectrum for luteolin (2)  
  
  
  
Figure S15. 1H-NMR spectrum for apigenin (3)  
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Figure S16. 13C-NMR spectrum for apigenin (3)  
 
 
  
Figure S17. DEPT spectrum for apigenin (3)  
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 Figure S18. HSQC spectrum for apigenin (3)  
 
 
Figure S19. HMBC spectrum for apigenin (3)  
  
59  
  
 
Figure S20. Mass spectrum for apigenin (3)  
 
  
  
Figure S21. IR spectrum for apigenin (3)  
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Figure S22. Chemical structures of the compounds isolated from Eriocephalus africanus, hesperidin 
(1), luteolin (2), and apigenin (3).  
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Figure S23. Cell viability of the ethyl acetate (EtOAc) fraction from the methanol (MeOH) extract of 
E. africanus and isolated compounds (hesperidin, luteolin, and apigenin) against (a) MCF-7, (b) 
A549, (c) HepG2 and (d) HEK 293 as determined by the MTT assay. Values are given as mean ± SD 
(n =3), *p < 0.05 from untreated cells, – **p < 0.05 from the positive control, 5- fluorouracil (5FU).  
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Figure S24. DPPH (a), reducing power scavenging activity (b), and nitric oxide (NO) radical 
scavenging activity (c) of the ethyl acetate (EtOAc) fraction from the methanol (MeOH) extract of 
Eriocephalus africanus. Values are given as mean ± SD, n =3.  
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 3.  CHAPTER THREE: MANUSCRIPT TWO  
  
3.1 The effect of hesperidin and luteolin isolated from Eriocephalus africanus on apoptosis, 
cell cycle and miRNA expression in MCF-7  
  
Submitted to: Journal of Biomolecular Structure and Dynamics (currently being considered for 
  
publication, corrections submitted).  
The phytochemical analysis of the methanolic extracts of E. africanus in chapter two, revealed 
E. africanus to be a rich source of flavonoids, which, upon exposure to MCF-7 cells, caused a 
significant dose-dependent decrease in cell viability. Subsequently, this chapter evaluates the 
molecular mechanisms implicated in the observed decrease in cell viability. Particularly, this 
chapter pays special attention to the effect of the isolated flavonoids on the apoptotic pathway. 
Dysregulated apoptotic function is a hallmark of cancer and it has been implicated in the 
pathogenesis of various types of cancer, including breast cancer. In this regard, identifying 
bioactive compounds inducing or restoring apoptotic function is a highly active and major 
approach in the search for alternative treatments for cancer.   
This chapter is formatted according to the journal specifications.  
 
 
 
  
 
 
  
  
    
64  
  
The effect of hesperidin and luteolin isolated from Eriocephalus africanus 
on apoptosis, cell cycle and miRNA expression in MCF-7  
Judie Maguraa, Roshila Moodleyb*, Irene Mackraja  
aSchool of Laboratory Medicine and Medical Sciences, University of KwaZulu–Natal,  
Durban, South Africa  
bSchool of Chemistry and Physics, University of KwaZulu–Natal, Durban, South Africa  
  
Abstract  
This study investigates the molecular mechanisms underlying the anticancer activity of 
hesperidin and luteolin, isolated from Eriocephalus africanus, in the human breast carcinoma 
cell line (MCF-7). The viability of MCF-7 cells, upon treatment with hesperidin and luteolin, 
was evaluated using the 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide 
(MTT) cytotoxicity assay; apoptotic activity and effect on cell cycle progression were analysed 
by flow cytometry; effect on expression of key apoptotic regulatory genes (caspase-3, -8, -9,  
Bcl-2 and Bax) and apoptotic microRNAs (-16, -21 and -34a) were evaluated using quantitative 
real-time PCR. Hesperidin and luteolin reduced cell viability in a dose and time-dependent 
manner, caused a significant accumulation of apoptotic cells into the G0/G1 and sub-G1 cell 
cycle phases, induced apoptosis through the intrinsic and extrinsic pathways, down-regulated 
anti-apoptotic, Bcl-2, and upregulated pro-apoptotic, Bax. In addition, hesperidin and luteolin 
significantly downregulated the expression of miR-21 and upregulated that of miR-16 and 34a 
in MCF-7. Pearson’s analysis revealed a positive correlation between Bcl-2 and miR-21 and 
negative correlation between Bcl-2, miR-16 and -34a. Findings from this study provide new 
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evidence on the molecular basis of the anticancer activity of luteolin and hesperidin in breast 
cancer cell lines.  
Keywords: flow cytometry, real-time PCR, breast cancer, apoptosis, flavonoids  
1. Introduction  
Cancer is one of the major causes of death worldwide and the number of cancer patients are 
continuously rising, with an estimated global increase of 26 million new cancer cases and  
17 million cancer deaths per year by 2030, according to the American Association for Cancer 
Research Report 2014 (Arteaga et al. 2014). To date, about 200 different types of cancers have 
been identified, with breast cancer being the most prevalent cancer among women, accounting 
for 1.5 million new cases per year, making it a global health threat (Hussain et al. 2019). Breast 
cancer is a complex heterogeneous disease; its progression and development are strongly linked 
to loss of cellular apoptotic function that is associated with accumulated alterations in genetic 
and epigenetic control (Abotaleb et al. 2019; Loh et al. 2019). Current evidence indicates that 
targeting the apoptotic pathway may be the most effective non-surgical treatment to combat 
breast cancer (Pfeffer & Singh 2018).  
Apoptosis, a genetic cell death mechanism, which serves to eliminate unwanted cells, is 
executed through two distinct pathways; the mitochondrial (intrinsic) pathway and death 
receptor (extrinsic) pathway (Venkatadri et al. 2016). The extrinsic pathway involves the cell 
surface binding of death receptors such as Fas, to death ligands (FasL), leading to caspase-
8mediated cell death. In contrast, the intrinsic pathway involves permeabilization of the 
mitochondrial outer membrane, mediated by Bcl-2 family proteins, leading to release of 
proapoptotic factors such as cytochrome c and subsequently caspase-9 initiated cell death 
(Green & Llambi 2015). After activation of the initiator caspases (-8 and -9), the two pathways 
converge on the effector caspases (-3 and -7), leading to apoptotic cell death with characteristic 
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biochemical and morphological changes (Pfeffer & Singh 2018). Several in vitro studies 
indicate that cellular death, induced by different stimuli in human breast cancer, is initiated 
through the mitochondrial pathway by the activation of caspase-3 and -9, and is often 
accompanied by the up-regulation of pro-apoptotic Bcl-2 family proteins (Bax, Bak and Bad), 
down-regulation of anti-apoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xL), the release of 
cytochrome c, production of mitochondrial ROS and cell cycle arrest  (Shahali et al. 2018; Sun 
et al. 2018; Jin et al. 2019). While the role of Bcl-2 in breast cancer is well known, recently 
microRNAs (miRNAs) have taken a central role in carcinogenesis and as therapeutic agents. 
Apoptosis-related miRNAs (apoptomiRs) post-transcriptionally regulate gene expression by 
binding with target mRNAs, generally in the 3′ untranslated region (3′ UTR), and control 
translation via degradation or repression (Sharma et al. 2016).   
To date, several miRNAs (including miR-15/16, -34a and -21) have been implicated in 
regulation of apoptosis and chemoresistance in breast cancer, through targeting key proteins  
(such as the Bcl-2 family) involved in cell death mechanisms (Loh et al. 2019). MiR-15 induced 
G1 cell cycle arrest and apoptosis through downregulation of the anti-apoptotic gene (Bcl -2) 
expression in breast cancer cell lines (Mei et al. 2015). Upregulation of miR-15 and 16, induced 
apoptosis in aloe-emodin treated MCF-7, via Bcl-2 repression (Jiang et al. 2020), and re-
sensitised breast cancer cells to tamoxifen treatment (Loh et al. 2019). Inactivation of miR21, 
a key oncomir in carcinogenesis and Bcl-2 regulator, also induced apoptosis, inhibited tumour 
progression and reversed doxorubicin resistance in breast cancer cells (Wang et al. 2011; 
Srivastava et al. 2015; Sharma et al. 2016). Moreover, upregulation of miR-34a inhibited cell 
proliferation in breast cancer cell lines (Imani et al. 2018; Cui & Placzek 2018) and altered 
docetaxel resistance of breast cancer cells through downregulation of Bcl-2 (Hu et al. 2018).  
Despite the advances in the current apoptosis targeting chemotherapies, toxicity and 
chemoresistance are drawbacks often observed in these therapies (Mohammad et al. 2015). 
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Hence, over the last two decades, there have been extensive studies on the use of naturally 
derived compounds as alternative apoptotic inducing, anticancer agents. Natural products 
account for over 50% of the drugs currently in clinical use, and globally, 80% of the population 
still utilize plant-derived medicines to alleviate their health problems (Millimouno et al. 2014). 
Moreover, studies suggest that natural phytocompounds could be more effective in cancer 
treatment than conventional treatments due to minimal side effects, their chemo-sensitising 
effects and their ability to target multiple cellular signalling pathways (Aung et al. 2017). 
Flavonoids are a group of natural polyphenolic metabolites comprising of two phenyl rings (A 
and B) joined by a heterocyclic ring C, which are widely distributed in plants (Dayem et al. 
2016). Structurally, flavonoids possess variations in the number and position of substituent 
groups across these rings, and a few studies have suggested that these structural variances may 
influence their biological activities, including anticancer properties (Tu et al. 2015; Menezes et 
al. 2016). These variations in substituents classify them into subgroups, including flavonols, 
flavones, flavanones and flavanols (Venkatarame et al. 2017). Hesperidin, a flavanone 
glycoside with a 7-O glycoside moiety and luteolin, a flavone aglycone with a 2,3-double bond, 
have both been shown to have anticancer, antitumor and antiproliferative activities in various 
human cancer cell models, in-vitro (Xia et al. 2018; Jang et al. 2019; Huang et al. 2019).   
The anticancer molecular mechanisms of action of hesperidin and luteolin in breast cancer is 
not well understood, and the correlation between apoptotic-related miRNAs and their target 
mRNA in hesperidin or luteolin-induced cell death against breast cancer is unknown. In this 
study, we investigate the anticancer activity of hesperidin and luteolin against MCF-7 cells by 
evaluating their effect on cell viability, cell cycle progression and expression of key apoptotic 
genes, such as Bcl-2, Bax and caspases, and apoptotic-related miRNAs, miR-16, -21 and -34a. 
We also investigated the influence of flavonoid structure on cytotoxicity and the correlation 
between the expression of miRNAs-and their target gene, Bcl-2.   
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2. Materials and Methods  
2.1. Chemicals  
All reagents used in this study were of analytical grade. Flavonoids, quercetin, apigenin, 
taxifolin, eriodictyol, hesperetin and chrysin, and positive the control (5-fluorouracil) were 
purchased from Sigma-Aldrich, Germany. Hesperidin and luteolin were previously isolated 
from Eriocephalus africanus (Magura et al. 2020). Hoechst 33342 and propidium iodide were 
obtained from ThermoFischer Scientific, USA.  
 
2.2. Cell culture  
Human MCF-7 cell lines obtained from American Tissue Culture Collection (ATCC) (Virginia, 
USA), were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin  
(Biowest, USA). Cells were maintained at 37 o C and 5% CO2 under humidified conditions.   
2.3. Cytotoxicity and analysis of structure-influence of flavonoids  
The cytotoxicity of hesperidin and luteolin on MCF-7 cell lines was evaluated using the 
standard MTT assay. In addition, to evaluate the influence of structure on cytotoxicity, a 
comparative study on the cytotoxic effect of flavonoids with slight differences in their structure 
to hesperidin and luteolin, namely, quercetin, apigenin, taxifolin, eriodictyol, chrysin and 
hesperetin, in MCF-7 cells, was also performed. Briefly, cells at 5 × 103 cells/well were seeded 
into 96-well plates (100 µL total medium volume) and allowed to attach overnight, then treated 
with concentrations of 20, 60, 100 and 140 µg/mL (in triplicate) of the tested flavonoids for 24 
h and 48 h. Untreated cells served as the negative control (control) and cells treated with 
5fluorouracil (5-FU) served as the positive control. After incubation, cell viability was 
measured via the MTT assay, and the absorbance was recorded at 560 nm using a microplate 
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reader (SPECTROstar Nano, BMG Germany). Data was presented as percentage cell viability 
relative to the untreated cells.  
2.4. Annexin V and PI staining  
Annexin V Apoptosis Kit 1 (BD PharmingenTM, California San Jose, USA) and flow cytometry 
were used to assess the apoptotic effects of hesperidin and luteolin in MCF-7 cells. Briefly, 
cells were seeded in 6-well plates and following overnight attachment, they were treated with 
flavonoids for 48 h at concentration of 100 µg/mL. Thereafter, cells were harvested using 
Accutase™ (ThermoFischer Scientific, USA) and collected by centrifugation at 2000 rpm for 
5 min. The collected cells were re-suspended in binding buffer, and an aliquot of 100 µL was 
treated with 5 µL of both Annexin V and PI and incubated for 15 min in the dark.  Thereafter, 
400 µL of binding buffer was added to each tube and analysed by flow cytometry within an 
hour.  
2.5. Morphology changes using Hoechst staining  
For the Hoechst staining, cells were seeded into 4-well glass slides (Lab-Tek® II, Chamber 
slide™) and treated with 100 µg/mL of hesperidin or luteolin for up to 48 h. Thereafter, cells 
were stained with 10 µg/mL of Hoechst and incubated for 30 min at room temperature. 
Subsequently, images were captured using the Floid® Cell Imaging Station under an excitation 
wavelength of 390/40 nm and an emission wavelength of 446/33nm for blue fluorescence.  
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2.6. Cell cycle analysis  
For all treatments at 48 h incubation, the cell cycle analysis was carried out according to the 
manufacturer`s protocol (BD Pharmigen™ FITC BrdU Flow Kit). Data was recorded in 
triplicate using a BD FACSCanto™ II flow cytometer and analysed with Kaluza 2.1 (Beckman 
Coulter) analysis software.  
2.7. Expression of mRNA using quantitative Real Time-PCR  
Total RNA was extracted from untreated and treated MCF-7 cells using a Quick-RNA 
MiniPrep kit (Zymo Research, CA, USA) according to the manufacturer`s protocol. The 
purified mRNA was transcribed into cDNA using reverse transcription and cDNA synthesis kit 
(SensiFast™, Bioline USA). The expression of the genes of interest were analysed using real-
time PCR and LightCycler® FastStart DNA Master SYBR Green (Roche Diagnostics, IN, 
USA). β-Actin was used as the reference gene to normalise the Cq values. The primer 
sequences used in this experiment are illustrated in Table 1. The cycling program was set as 
follows: DNA polymerase was activated for 10 min at 95 °C followed by 45 cycles consisting 
of a denaturing step for 15 s at 95 °C, and annealing/extension step for 30 s at 60 °C and 72°C 
for 30 s (Fani et 2016). The 2-ΔΔCq comparative method was used to calculate the fold change 
in gene expression in response to treatment with luteolin and hesperidin (Schmittgen & Livak 
2008; Xie et al. 2018).  
  
  
  
  
  
71  
  
Table 1. Primer sequences for quantitative Real Time-PCR  
  
Gene Forward Reverse References 
β-actin  5′-GCACCACACCTTCTACAATG -3′  5′-TGCTTGCTGATCCACATCTG-3′ Khan et al. 
2016 
Bcl-2 5′-GGCTGGGATGCCTTTGTG-3′   5′-CAGCCAGGAGAAATCAAACAGA-3′ Khan et al. 
2016 
Bax 5′-TGCTTCAGGGTTTCATCCAG-3′ 5′-GGCGGCAATCATCCTCTG -3′ Khan et al. 
2016 
Caspase-3 5′- CAGAACTGGACTGTGGCATTG-3′ 5′-GCTTGTCGGCATACTGTTTCA-3′ Khan et al. 
2016 
Caspase-8 5′-CATCCAGTCACTTTGCCAGA-3′ 5′-GCATCTGTTTCCCCATGTTT-3′ Pilco-Ferreto 
& Calaf 2016 
Caspase-9 5′-CCAGAGATTGCGAAACCAGAGG-
3′ 
5'-GAGCACCGACATCACCAAATTC-3' Pilco-Ferreto 
& Calaf 2016 
 
2.8. Quantitative Real-Time –PCR analysis of miRNA expression  
MiRNAs were isolated from the treated and untreated cells using the PureLink miRNA 
isolation kit according to the manufacturer’s protocol. Complementary DNA (cDNA) was 
synthesised using the SensiFast™ cDNA synthesis kit (Bioline, USA), after which, the miRNA 
expression was determined using real-time PCR and SYBR green master mix (Roche  
Diagnostics, IN, USA). U6 was used to normalise the Cq values and as the reference gene. 
Specific miRNA primers used in this experiment were as follows: miR-16, Forward; 
5′TAGCAGCACGTAAATATTGGCG-3′, Reverse; 5'-CCAGTATTGACTGTGCTGCTGA-
3', miR-21, Forward; 5′- GGGGATTTCTTGGTTTGTGAA-3′ and Reverse 
5′ATACAGCTAGAAAAGTCCCTGAAAA-3′ and miR-34a, Forward; 5′- 
GCGGCCAATCAGCAAGTATACT-3′, Reverse; 5′-GTGCAGGGTCCGAGGT-3′ (Zhou et  
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al. 2018; L. Zhang et al. 2018). The miRNAs expression was calculated using the 2-ΔΔCq 
comparative method.    
2.9. Statistical Analysis  
All experiments were carried out in triplicate and data was expressed as mean ± standard 
deviation.  For statistical significance, the one-way analysis of variance (ANOVA) with 
Tukey`s post hoc at p < 0.05 was performed, using GraphPad Prism software (La Jolla, CA). 
The Pearson’s correlation test was computed using Microsoft Excel Data Analysis ToolPak to 
evaluate the correlation between miRNAs and their target mRNA.   
  
3. Results  
3.1. Cytotoxicity of hesperidin and luteolin, and structure-influence of flavonoids on 
cytotoxicity.    
MCF-7 cells treated with hesperidin and luteolin at concentrations 20, 60, 100 and 140 µg/mL 
for 24 h and 48 h showed decreased cell viability in a dose and time-dependent manner (Figure 
1). Treatment with 100 or 140 µg/mL effectively reduced cell viability to approximately 36% 
for hesperidin and 15% for luteolin after 48 h. Since no statistically significant difference (p < 
0.05) was observed for treatments at both concentrations, 100 µg/mL at 48 h was selected for 
proceeding experiments. The MTT structure-influence analysis confirmed that the cytotoxic 
activity of flavonoids is influenced by structure with activity at 100 µg/mL for 48 h increasing 
in the order of taxifolin < eriodictyol < chrysin < quercetin < hesperidin ≈ hesperetin < apigenin  
≈ luteolin (Supplementary Figure 1(a)-(d)).  
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Figure 1. Cytotoxicity of (a) hesperidin and (b) luteolin at 24 h and 48 h in MCF-7. The results are 
represented as mean ± SD of three experimental replicates, * significant difference at p < 0.05 from the 
control and # from the 20 and 60 µg/mL group, at p < 0.05. 
 
3.2. Annexin V-FITC and PI staining  
To establish whether the cell death observed after treating MCF-7 with hesperidin and luteolin, 
was due to apoptosis or necrosis, Annexin V-FITC and PI staining followed by flow cytometric 
analysis was performed. The results show a significant increase in apoptotic cell populations   
for both hesperidin (56 ± 3.14%) and luteolin (83.6 ±0.71%) treated cells, in contrast to the 
control (0.04 ± 0.00%) (Figure 2).  
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Figure 2. Apoptotic effects of hesperidin, luteolin and 5-fluorouracil (5-FU) on MCF-7 48 h post-
treatment. The bar graph represents total percentage of apoptotic cells in quadrants A-+, early apoptotic 
and A++, late apoptotic. Values are represented as mean ± SD of three independent experiments, * 
statistically significant difference from the control (untreated cells) at p < 0.05. 
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3.3. Morphological changes  
To further confirm the apoptotic effect of hesperidin and luteolin, hesperidin and luteolin 
treated cells were stained with Hoechst 33342 and examined microscopically using Floid® 
Live Cell Imaging Station. Hoechst 33342 is a cell permeable dye which emits blue 
fluorescence when bound to DNA, allowing the visualisation of the cell nuclei and 
identification of apoptotic makers. Apoptotic morphological changes were observed in 
hesperidin and luteolin treated MCF-7 cells, as illustrated in Figure 3.  
 
  
Figure 3. Morphological changes in hesperidin and luteolin treated MCF-7 cells at 100 µg/mL for 48 
h, 5-fluorouracil (5-FU) and control (untreated cells). Hoechst 33342 was used for staining and 
micrographs were captured using Floid® Live Cell Imaging Station. The red arrows indicate nuclear 
fragmentation and condensation.   
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3.4. Cell cycle analysis  
To assess if the apoptotic effect was subsequently due to cell cycle arrest, the changes in the 
cell cycle upon treatment with hesperidin or luteolin at 100 ug/mL for 48 h were investigated.    
 
 
Figure 4. Cell cycle analysis after treatment with (a) hesperidin, (b) luteolin and (c) 5fluorouracil (5-
FU) at 100 ug/mL for 48 h. The bar graphs represent the total percent cell population in different phases. 
Values are shown as mean ± SD of experimental triplicates, * significant difference at p < 0.05. 
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Hesperidin treatment resulted in a significant accumulation of cell population in the G0/G1 
phase (50%), suggesting cell cycle arrest in the G0/G1 phase. Treatment with luteolin showed 
higher accumulation of cell populations in the apoptotic or sub G1 phase 53% vs. 28.6% in 
G0/G1, 3.3% in S phase and 8.9% in the G2+M phase (Figure 4).   
  
3.5. Changes in apoptotic gene expression on hesperidin and luteolin treatment  
To establish the molecular pathway of the hesperidin and luteolin-induced apoptosis in MCF7 
cells, the expression of caspase-9 (intrinsic) and caspase-8 (extrinsic) were analysed using real-
time PCR, 48 h post-treatment. Since the intrinsic and extrinsic pathways converge (Pfeffer & 
Singh 2018), increased levels of caspase-3 have also been associated with activation of both 
apoptotic pathways; therefore, the expression of caspase-3 was also evaluated. The results 
showed an increase in the expression of caspase-3 and -9 in hesperidin treated cells and an 
increase in expression of both caspase-9 and -8 in luteolin treated cells (Figure 5a). 
Additionally, an increase in the expression of pro-apoptotic proteins Bax and decrease in 
antiapoptotic proteins Bcl-2, were observed (Figure 5b).  
 
Figure 5. Expression of (a) caspase-3, -8 and -9 and (b) Bax and Bcl-2 in hesperidin and luteolin treated 
MCF-7 cells at 100 ug/mL for 48 h. Data is represented as mean ± SD, * significant difference at p < 
0.05 vs control and # at p < 0.05 vs hesperidin treated. 
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3.6. Effect of hesperidin and luteolin on miRNA expression  
To further evaluate the molecular pathway of hesperidin and luteolin, expression levels of 
miR16, -21, and -34a were assessed in hesperidin and luteolin treated MCF-7 cells. The 
quantitative analysis showed a significant increase, relative to the control, in the expression 
levels of miR16 and -34a, and downregulation of miR-21 in hesperidin treated cells (Figure 6). 
Treatment with luteolin showed an approximately 2.4-fold increase in both miR-16 and -34a 
expression (Figure 6), and a decrease in the expression of miR-21, 48 h post-treatment.   
  
 
 
 
 
 
 
Figure 6. Expression of miR-16, -21 and -34a in hesperidin and luteolin treated MCF-7 cells at 100 
ug/mL for 48 h. Values represented as mean ± SD, * significant difference at p < 0.05 vs control and # 
significant different at p < 0.05 vs hesperidin treated. 
 
3.7. Correlation analysis of miRNAs and their target mRNA  
The correlations among miR-16, -21, -34a, and mRNA, Bcl-2 were evaluated using the Pearson 
correlation test. The Pearson`s test showed a negative correlation between the expression of 
miR-16, -34a and target Bcl-2, r (2) = -0.73, p < 0.05, two-tailed and a strong positive 
correlation between miR-21 and Bcl-2, r (2) =1, with no significant difference, p = ns, 
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twotailed. Overall, an increase in expression of miR-16 and -34a was correlated with a decrease 
in expression of Bcl-2, whereas, a decrease in miR-21 was associated with a decrease in Bcl-2 
as well.  
4. Discussion  
Evasion of apoptosis is a hallmark of cancer, hence, induction or reactivation of apoptosis by 
cytotoxic anticancer agents, is a key approach in the development of novel, promising 
therapeutic strategies for cancer treatment (Jaudan et al. 2018). Many reports on natural 
product-derived flavonoids, have shown that they inhibit proliferation and induce apoptosis in 
cancer cells. For example, Zhang et al. (2018) demonstrated that flavonoids, isorhamnetin, 
genkwanin and acacetin, isolated from Tephroseris kirilowii, inhibited cell proliferation 
through the induction of apoptotic cell death and G2/M phase cell cycle arrest. Similarly, 
catechin, also a plant-derived flavonoid, reduced cell proliferation and induced apoptosis in 
murine lymphoma cells LB02 via modulation of antiapoptotic proteins (Papademetrio et al. 
2013).  
In this study, two flavonoids, hesperidin and luteolin, which we previously isolated from 
Eriocephalus africanus, exhibited cytotoxicity against the breast cancer cell line (MCF-7) in a 
dose and time-dependent manner (Figure 1). In addition, flavonoid structure was shown to have 
an influence on cytotoxicity (Supplementary Figure 1(a)-(d)). The flavone (luteolin), with a 
2,3-double bond and carbonyl at position 4 in the C-ring, presented higher cytotoxicity in 
comparison to the flavanone, eriodictyol, with no double bond in the C-ring. The additional 
hydroxyl group in the B-ring of luteolin compared to apigenin, did not influence the 
cytotoxicity of flavones; however, removal of the hydroxyl groups from the B-ring, as in 
chrysin, considerably reduced the cytotoxicity of the flavone. Addition of the hydroxyl group 
to position 3 of the C-ring, as in quercetin, reduced the cytotoxicity of the flavonol relative to 
luteolin. Similarly, addition of the hydroxyl group to position 3 of the flavanonol, taxifolin, 
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reduced cytotoxicity compared to eriodictyol. Replacement of a hydroxyl group in the B-ring 
of eriodictyol with a methoxy group, as in hesperetin, considerably increased cytotoxicity of 
the flavanone whilst further addition of a sugar moiety to position 7 of the A-ring, did not 
noticeably affect cytotoxicity, as is seen in the glycoside, hesperidin. The results indicate that 
flavonoid structures that present with a double bond in the C-ring and hydroxyl or methoxy 
substituents in the B-ring, positively influenced cytotoxicity whilst structures with a hydroxyl 
group at position 3 of the C-ring negatively affect cytotoxicity.  Menezes et al. (2016), also 
demonstrated structural influences in several flavonoids for the treatment of leukaemia. A study 
on the cytotoxicity of flavonoids towards cultured normal human cells by Matsuo et al. (2005) 
suggested that, if flavonoids are efficiency incorporated into cells, they tend to generate more 
intracellular reactive oxygen species that then exert cytotoxicity on cells.   
These findings suggest that factoring structural influences in anticancer activity, could be useful 
in developing effective drugs for treatment.  Furthermore, the cytotoxicity of hesperidin and 
luteolin was confirmed to be apoptotic-induced, as demonstrated by the Annexin V/ PI and 
flow cytometric analysis (Figure 2), and treatment with both hesperidin and luteolin (100 
ug/mL for 48 h) resulted in the accumulation of apoptotic cell populations of 56 ± 3.14% and 
83.6 ± 0.71%, respectively. Furthermore, microscopic evaluation (Figure 3) of hesperidin and 
luteolin treated cells exhibited typical morphological features of cells undergoing apoptosis, 
such as chromatin condensation and nuclear fragmentation, accompanied by reduction in cell 
population (Syed Abdul Rahman et al. 2013). Increasing evidence suggests that the induction 
of apoptosis, associated with cell cycle arrest, is a viable approach for anticancer agents (X. Li 
et al. 2018; Zhang et al. 2018). Flow cytometric analysis in this study revealed significant 
accumulation of MCF-7 cells in the G0/G1 and sub-G1 phases, 48 h post-treatment with 
hesperidin and luteolin, respectively. These results suggest that hesperidin induces cell cycle 
arrest in the G0/G1 phase, inhibiting the entry of DNA damaged cells into the S phase, and 
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possibly eliminating them through apoptosis. On the other hand, luteolin showed inhibition of 
cell cycle progression through sub-G1 arrest.  
Disruption in mitochondrial function in response to apoptotic stimuli in the intrinsic pathway, 
results in activation of caspase-9 followed by effector caspase-3, leading to apoptotic cell death. 
This pathway is controlled by the Bcl-2 family proteins, including Bax and Bid, inducing 
apoptosis, and Bcl-2 and Bcl-xL inhibiting apoptosis (Green & Llambi 2015). Thus, elevated 
expression levels of caspase-3 and -9 coupled with upregulation of pro-apoptotic Bax and 
downregulation Bcl-2 (Figure 5), confirmed that hesperidin and luteolin-induced apoptosis in 
MCF-7, could be through the intrinsic apoptotic pathway. Interestingly, treatment with luteolin 
also resulted in significantly increased expression of caspase-8 (Figure 5a), suggesting that it 
could be multi-signalling and may induce apoptosis in MCF-7 through both the extrinsic and 
intrinsic pathways. Our observations pertaining to  hesperidin and luteolin-induced apoptosis 
is in keeping with previous studies on the pro-apoptotic activity of hesperidin and luteolin in 
other cancer cells, including human NSCLC A549 via mitochondria-mediated apoptosis (Xia 
et al. 2018), MDA‐MB‐231 through  novel downregulation of hTERT (Huang et al. 2019), and 
HeLa cells via a caspase-dependent pathway with G0/G1 cell cycle arrest (Wang et al. 2015).  
There are no previous reports on the effect of flavonoids (hesperidin or luteolin) on apoptosis-
related miRNAs and their correlation with their target genes. MicroRNAs have been implicated 
in several biological pathways, including apoptosis, cell cycle regulation, tumour progression, 
metastasis, cancer recurrence and chemo-resistance (Zadeh et al. 2016; Loh et al. 2019). In the 
present study, the expression of miR-16, -21, -34a, and their target gene Bcl-2 was assessed 48 
h post-treatment with 100 ug/mL of hesperidin or luteolin. Treatment with hesperidin and 
luteolin resulted in the upregulation of miR-16 and -34a, and downregulation of miR-21 and 
Bcl-2 (Figure 5b and 6). Other studies demonstrated miR-16 and -34a as pro-apoptotic, 
negatively regulating anti-apoptotic Bcl-2 genes and acting as tumour suppressors in breast 
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cancer cell lines (Sharma et al. 2016). Furthermore, upregulation of miR-16 and -34a was 
shown to promote apoptosis and cell cycle arrest in several in vitro studies (Momen-Heravi & 
Bala 2016; Mondal et al. 2019). On the other hand,  miR-21  is an established, overexpressed 
oncomir in breast cancer, and various studies implicate its knockdown or downregulation with 
apoptosis induction, decreased cell proliferation,  and re-sensitisation of cells to treatment (Du 
et al. 2017; Hu et al. 2018; F. Li et al. 2018; G. Li et al. 2018). Our results suggest that, in 
addition to modulation of key apoptosis related mRNA and activation of caspase, hesperidin 
and luteolin also induced apoptosis in MCF-7 through modulation of apoptotic miRNAs (viz 
miR-16, -21 and -34a). Modulation of the miRNAs could also have sensitised MCF-7 cells to 
hesperidin and luteolin treatment.   
Furthermore, Pearson`s analysis revealed that the expression of miR-16 and -34a was inversely 
correlated with the expression of the target gene Bcl-2, as confirmed by the negative correlation. 
A positive correlation was observed between the expression of miR-21 and Bcl-2, indicating a 
co-downregulation of miR-21 and Bcl-2. It may be noted that cancer studies involving mRNA 
should include miRNA, as the modulators of these genes, thereby providing further anticancer 
targets. It is apparent from the correlations, that epigenetic control is a key aspect of cancer 
therapy.  
  
5. Conclusion  
This study demonstrated that the anticancer activity of natural polyphenolic flavonoids, 
hesperidin and luteolin, was mediated through the reduction of cell viability, inhibition of cell 
cycle progression, intrinsic and extrinsic apoptotic pathways with upregulation of proapoptotic 
Bax gene, and downregulation of the anti-apoptotic Bcl-2 gene. Furthermore, this study 
provides new insights on the effect of hesperidin and luteolin on the expression of apoptotic 
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miRNAs and their relationship with their target genes, broadening the understanding of 
molecular mechanisms involved in flavonoid-induced cell death.   
 
Conflict of interest  
The author(s) confirm no conflict of interest.  
Acknowledgments  
The author(s) are grateful to the University of KwaZulu-Natal, College of Health Sciences 
under [Grant number 636742], and the National Research Foundation of South Africa through 
Dr. Roshila Moodley [Grant number 114008] for their financial support.  
  
  
  
  
  
  
  
  
  
  
  
84  
  
References  
Abotaleb M, Samuel SM, Varghese E, Varghese S, Kubatka P, Liskova A, Büsselberg D.  
2019. Flavonoids in cancer and apoptosis. Cancers (Basel). 11.  
Arteaga CL, Adamson PC, Engelman JA, Gaynor RB, Hilsenbeck SG, Limburg PJ, Lowe SW, 
Mardis ER, Ramsey SD, Rebbeck TR, et al. 2014. Cancer Progress Report 2014.  
Clin Cancer Res.: clincanres.2123.2014.  
Aung T, Qu Z, Kortschak R, Adelson D, Aung TN, Qu Z, Kortschak RD, Adelson DL. 2017. 
Understanding the effectiveness of natural compound mixtures in cancer through their 
molecular mode of action. Int J Mol Sci. 18:656.  
Cui J, Placzek WJ. 2018. Post-transcriptional regulation of anti-apoptotic BCL2 family 
members. Int J Mol Sci. 19.  
Dayem AA, Choi HY, Yang GM, Kim K, Saha SK, Cho SG. 2016. The anti-cancer effect of 
polyphenols against breast cancer and cancer stem cells: Molecular mechanisms.  
Nutrients. 8.  
Du G, Cao D, Meng L. 2017. MiR-21 inhibitor suppresses cell proliferation and colony 
formation through regulating the PTEN/AKT pathway and improves paclitaxel 
sensitivity in cervical cancer cells. Mol Med Rep. 15:2713–2719.  
Green DR, Llambi F. 2015. Cell death signaling. Cold Spring Harb Perspect Biol. 7.  
Hu WZ, Tan CL, He YJ, Zhang GQ, Xu Y, Tang JH. 2018. Functional miRNAs in breast cancer 
drug resistance. Onco Targets Ther. 11:1529–1541.  
Huang L, Jin K, Lan H. 2019. Luteolin inhibits cell cycle progression and induces apoptosis 
of breast cancer cells through downregulation of human telomerase reverse 
transcriptase. Oncol Lett. 17:3842–3850.  
85  
  
Hussain S, Cevik E, Tombuloglu H, Farag K, Said O. 2019.  miRNA profiling in MCF-7 breast 
cancer cells: Seeking a new biomarker. J Biomedical Sci.8(2):3.  
Imani S, Wu R-C, Fu J. 2018. MicroRNA-34 family in breast cancer: from research to 
therapeutic potential. J Cancer. 9.  
Jang CH, Moon N, Oh J, Kim JS. 2019. Luteolin shifts oxaliplatin-induced cell cycle arrest at 
g0/g1 to apoptosis in hct116 human colorectal carcinoma cells. Nutrients. 11:1–14.  
Jaudan A, Sharma S, Malek SNA, Dixit A. 2018. Induction of apoptosis by pinostrobin in 
human cervical cancer cells: Possible mechanism of action.Hsieh Y-H, editor. PLoS 
One. 13: e0191523.  
Jiang X, Liu Y, Zhang G, Lin S, Wu J, Yan X, Ma Y, Ma M. 2020. Aloe-emodin induces 
breast tumor cell apoptosis through upregulation of miR-15a/miR-16-1 that suppresses 
BCL2. Evid Based Complementary Altern Med. 11:1-10.  
Jin H, Ko YS, Park SW, Chang KC, Kim HJ. 2019. 13-Ethylberberine induces apoptosis 
through the mitochondria-related apoptotic pathway in radiotherapy-resistant breast 
cancer cells. Molecules. 24.  
Khan F, Ahmed F, Pushparaj PN, Abuzenadah A, Kumosani T, Barbour E, AlQahtani M, 
Gauthaman K. 2016. Ajwa Date (Phoenix dactylifera L.) extract inhibits human breast 
adenocarcinoma (MCF7) cells in vitro by inducing apoptosis and cell cycle arrest.  
PLoS One. 11:1-27.  
Li F, Lv JH, Liang L, Wang J chao, Li CR, Sun L, Li T. 2018. Downregulation of microRNA21 
inhibited radiation-resistance of esophageal squamous cell carcinoma. Cancer Cell Int. 
18:39.  
86  
  
Li G, Song Y, Li Gangcan, Ren J, Xie J, Zhang Y, Gao F, Mu J, Dai J. 2018. Downregulation 
of microRNA-21 expression inhibits proliferation and induces G1 arrest and apoptosis 
via the PTEN/AKT pathway in SKM-1 cells. Mol Med Rep. 18:2771–2779.  
Li X, Qiu Z, Jin Q, Chen G, Guo M. 2018. Cell cycle arrest and apoptosis in HT-29 cells 
induced by dichloromethane fraction from Toddalia asiatica (L.) Lam. Front Pharmacol. 
9:629.  
Loh HY, Norman BP, Lai KS, Rahman NMANA, Alitheen NBM, Osman MA. 2019. The  
regulatory role of microRNAs in breast cancer. Int J Mol Sci. 20.  
Magura J, Moodley R, Maduray K, Mackraj I. 2020. Phytochemical constituents and in vitro 
anticancer screening of isolated compounds from Eriocephalus africanus. Nat Prod Res. 
DOI: 10.1080/14786419.2020.1744138  
Matsuo M, Sasaki N, Saga K, Kaneko T. 2005. Cytotoxicity of flavonoids toward cultured 
normal human cells. Biol. Pharm. Bull. 28:253–259.  
Mei Z, Su T, Ye J, Yang C, Zhang S, Xie C. 2015. The miR-15 family enhances the 
radiosensitivity of breast cancer cells by targeting G2 checkpoints. Radiat Res. 183:196– 
207.  
Menezes JCJMDS, Orlikova B, Morceau F, Diederich M. 2016. Natural and synthetic 
flavonoids: structure–activity relationship and chemotherapeutic potential for the 
treatment of leukemia. Crit Rev Food Sci Nutr. 56: S4–S28.  
Millimouno FM, Dong J, Yang L, Li J, Li X. 2014. Targeting apoptosis pathways in cancer and 
perspectives with natural compounds from mother nature. Cancer Prev Res. 7:1081– 
1107.  
Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C,  
87  
  
Kumar NB, Dou QP, et al. 2015. Broad targeting of resistance to apoptosis in cancer. 
Semin Cancer Biol. 35: S78–S103.  
Momen-Heravi F, Bala S. 2016. The miRNA and extracellular vesicles in alcoholic liver 
disease. In: Mol Asp Alcohol Nutr A Vol Mol Nutr Ser. [place unknown]: Elsevier Inc; 
p. 275–286.  
Mondal I, Sharma S, Kulshreshtha R. 2019. MicroRNA therapeutics in glioblastoma: 
Candidates and targeting strategies. In: AGO-Driven Non-Coding RNAs. [place 
unknown]: Elsevier; p. 261–292.  
Papademetrio DL, Trabucchi A, Cavaliere V, Ricco R, Costantino S, Wagner ML, Álvarez E. 
2013. The catechin flavonoid reduces proliferation and induces apoptosis of murine 
lymphoma cells LB02 through modulation of antiapoptotic proteins. Brazilian J 
Pharmacogn. 23:455–463.  
Pfeffer CM, Singh ATK. 2018. Apoptosis: A target for anticancer therapy. Int J Mol Sci. 19.   
Pilco-Ferreto N, Calaf GM. 2016. Influence of doxorubicin on apoptosis and oxidative stress 
in breast cancer cell lines. Int J Oncol. 49.  
Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative C(T) 
method. Nat Protoc. 3:1101–8.  
Shahali A, Ghanadian M, Jafari SM, Aghaei M. 2018. Mitochondrial and caspase pathways are 
involved in the induction of apoptosis by nardosinen in MCF-7 breast cancer cell line. 
Res Pharm Sci. 13:12–21.  
Sharma S, Patnaik PK, Aronov S, Kulshreshtha R. 2016. ApoptomiRs of breast cancer: Basics 
to clinics. Front Genet. 7.  
88  
  
Srivastava SK, Arora S, Averett C, Singh S, Singh AP. 2015. Modulation of micrornas by 
phytochemicals in cancer: Underlying mechanisms and translational significance. 
Biomed Res Int. 2015.  
Sun X, Zhang H, Zhang Y, Yang Q, Zhao S. 2018. Caspase-dependent mitochondrial apoptotic 
pathway is involved in astilbin-mediated cytotoxicity in breast carcinoma cells. Oncol 
Rep. 40:2278–2286.  
Syed Abdul Rahman SN, Abdul Wahab N, Abd Malek SN. 2013. In vitro morphological 
assessment of apoptosis induced by antiproliferative constituents from the rhizomes of 
Curcuma zedoaria. Evidence-based Complement Altern Med. 2013.  
Tu B, Chen Z-F, Liu Z-J, Li R-R, Ouyang Y, Hu Y-J. 2015. Study of the structure-activity 
relationship of flavonoids based on their interaction with human serum albumin. RSC 
Adv. 5:73290–73300.  
Venkatadri R, Muni T, Iyer AKV, Yakisich JS, Azad N. 2016. Role of apoptosis-related 
miRNAs in resveratrol-induced breast cancer cell death. Cell Death Dis. 7: e2104.  
Venkatarame V, Saralamma G, Kim EH, Lee HJ, Raha S, Lee WS, Doo J. 2017. Flavonoids: 
A new generation molecule to stimulate programmed cell deaths in cancer cells. J  
Biomed Transl Res. 18:30–37.  
Wang Y, Yu H, Zhang J, Gao J, Ge X, Lou G. 2015. Hesperidin inhibits HeLa cell proliferation 
through apoptosis mediated by endoplasmic reticulum stress pathways and cell cycle 
arrest. BMC Cancer 2015 151. 15:1–11.  
Wang ZX, Lu B Bin, Wang H, Cheng ZX, Yin YM. 2011. MicroRNA-21 modulates  
chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch Med Res. 
42:281–290.  
89  
  
Xia R, Sheng X, Xu X, Yu C, Lu H. 2018. Hesperidin induces apoptosis and GO/G1 arrest in 
human non-small cell lung cancer A549 cells. Int J Mol Med. 41:464–472.  
Xie X, Huang Y, Chen L, Wang J. 2018. miR-221 regulates proliferation and apoptosis of 
ovarian cancer cells by targeting BMF. Oncol Lett. 16:6697–6704.  
Zadeh MM, Motamed N, Ranji N, Majidi M, Falahi F. 2016. Silibinin-induced apoptosis and 
downregulation of microRNA-21 and MicroRNA-155 in MCF-7 human breast cancer 
cells. J Breast Cancer. 19:45–52.  
Zhang H-W, Hu J-J, Fu R-Q, Liu X, Zhang Y-H, Li J, Liu L, Li Y-N, Deng Q, Luo Q-S, et 
al.2018.  Flavonoids inhibit cell proliferation and induce apoptosis and autophagy 
through downregalation of PI3Kγ mediated PI3K/AKT/mTOR/p70S6K/ULK in human  
breast cancer cells. Sci Rep. 8:11255.                                   
Zhang L, Zhou L, Shi M, Kuang Y, Fang L. 2018. Downregulation of miRNA-15a and miRNA-
16 promote tumor proliferation in multiple myeloma by increasing CABIN1 expression. 
Oncol Lett. 15:1287–1296.  
Zhou Y, Ding BZ, Lin YP, Wang HB. 2018. MiR-34a, as a suppressor, enhance the  
susceptibility of gastric cancer cell to luteolin by directly targeting HK1. Gene. 644:56– 
65.  
 
 
 
 
 
 
 
 
90  
  
SUPPLEMENTARY MATERIAL 
  
The effect of hesperidin and luteolin isolated from Eriocephalus africanus on 
apoptosis, cell cycle and miRNA expression in MCF-7 
Judie Maguraa, Roshila Moodleyb*, Irene Mackraja.  
aSchool of Laboratory Medicine and Medical Sciences, University of KwaZulu–Natal,  
Durban, South Africa  
bSchool of Chemistry and Physics, University of KwaZulu–Natal, Durban, South Africa  
  
*Corresponding author: Roshila Moodley; School of Chemistry and Physics, College of 
Agriculture, Engineering and Science, University of KwaZulu-Natal (Westville), P.O. Box:  
X54001, Durban, South Africa; Tel/Fax: +27 31 260 8127, +27 84 606 7710; E-mail: 
Moodleyrosh@ukzn.ac.za  
  
  
  
  
  
  
  
91  
  
  
1. Structural influence of flavonoids on cytotoxicity in MCF-7 cells  
To evaluate the structural influence of flavonoids on cytotoxicity in MCF-7, the effect of 
flavonoids with slight differences in their moiety viz; hesperidin, luteolin, quercetin, apigenin, 
taxifolin, eriodictyol, chrysin and hesperetin, on  MCF-7 cell viability was investigated using 
the MTT assay. The results are illustrated in Figure S1.  
  
Figure S1. Cytotoxic activity of different flavonoids in MCF-7 at concentrations of 20 – 140 µg/mL 
and 48 h incubation. (a) represents comparative cytotoxicity among flavonoids with variation in -OH 
substitution in the B-ring, (b) flavonoids with or without a 2,3-double bond in the C-ring and -OH 
substitution, (c) flavonoids with or without a glycol moiety. Values are presented as mean ± SD of three 
experimental replicates, *, statistically significant difference at p < 0.05. 
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Figure S2. Molecular structures of flavonoids with varying -OH substitution in the B-ring  
  
 
Figure S3. Molecular structures of flavonoids with or without the 2,3 double bond and varying -OH 
substitution in the C-ring  
 
Figure S4. Molecular structures of flavonoids with or without the glycol moiety.  
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2. 1H NMR spectra of the flavonoids  
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 4.  CHAPTER FOUR: MANUSCRIPT THREE  
  
4.1 Hesperidin-loaded nanoemulsions improve cytotoxicity, induces apoptosis and 
downregulates miR-21 and miR-155 expression in MCF-7  
  
Submitted to: Journal of Drug Targeting  
  
Chapter three demonstrated the therapeutic potential of the isolated flavonoids in breast cancer 
as evidenced by their effect on the apoptotic pathway, the expression of key apoptotic miRNAs 
and cell cycle progression in MCF-7, a luminal A breast cancer model. However, literature has 
shown flavonoids to generally have low bioavailability and poor solubility in aqueous media 
which often hampers their clinical application. During our preparations and experimental 
investigations, we also observed the acclaimed poor aqueous solubility; therefore, we designed 
nanosystems to circumvent these drawbacks. The biosafety evaluations of the hesperidin and 
luteolin nano-formulations proved the synthesised hesperidin-loaded nanoemulsions to be safe, 
in contrast to the luteolin nano-formulation. Therefore, chapter four details their synthesis and 
characterisation, and further explores the anticancer potential of the novel hesperidin-loaded 
nanoemulsions.  
This chapter is formatted according to the journal specifications.  
 
 
 
 
 
 
 
    
99  
  
Hesperidin-loaded nanoemulsions improve cytotoxicity, induces apoptosis 
and downregulates miR-21 and miR-155 expression in MCF-7 
Judie Maguraa, Daniel Hassanb, Roshila Moodleyc*, Irene Mackraja.  
a School of Laboratory Medicine and Medical Sciences, University of KwaZulu–Natal,  
Durban, South Africa  
bDiscipline of Pharmaceutical Sciences, University of KwaZulu–Natal, Durban, South Africa   
cSchool of Chemistry and Physics, University of KwaZulu–Natal, Durban, South Africa  
  
Abstract  
Hesperidin, a ubiquitous plant-based flavanone, demonstrates excellent therapeutic properties, 
but due to poor solubility and bioavailability, its therapeutic effects are limited. Therefore, in 
this study, hesperidin was encapsulated into nanoemulsions (HP-NEM) to improve its 
solubility and achieve enhanced bioavailability and efficacy in breast cancer treatment using 
MCF-7 cell lines. Furthermore, this study assessed the cytotoxic and apoptotic effects of HP-
NEM against MCF-7 and their effects on oncomiRs, microRNA-21 and microRNA-155 
expression. A spontaneous emulsification method was used to formulate HP-NEM and its 
physicochemical properties were evaluated. The optimised HP-NEM displayed a spherical 
shape with 305 ± 40.8 nm, 0.308 ± 0.04, -11.6 ± 3.30 mV and 93 ± 0.45% for particle size, 
polydispersity index (PDI), zeta-potential (ζ) and encapsulation efficiency, respectively. The 
in vitro drug release profile demonstrated a sustained release of hesperidin from the 
nanoemulsions over a 48 h period. Cytotoxicity studies using MTT assay, showed selective 
toxicity of the HP-NEM against MCF-7, without affecting normal cells (HEK 293). Treatment 
with the HP-NEM induced cell death through apoptosis, cell cycle arrest in the G2/M phase 
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and downregulated miR-21 and miR-155 expression in MCF-7. This study supports the use of 
HP-NEM as a potential therapeutic agent in breast cancer treatment.   
  
Keywords:  Breast cancer, hesperidin, nanoemulsions, miR-21, miRNA-155 downregulation  
  
Introduction  
Breast cancer is one of the most frequently diagnosed malignancies in women and is the second-
highest cause of cancer death, worldwide [1,2]. Over the last ten years, there have been 
significant advancements in understanding the genetic and molecular basis of breast cancer [3], 
leading to a heightened interest in unravelling effective therapeutic approaches for the 
alleviation of the breast cancer pandemic.   
Hesperidin, a naturally occurring 3’,5,7-trihydroxy-4’-methoxy flavanone glycoside, 
commonly found in citrus fruits, was recently isolated from Eriocephalus africanus (wild 
rosemary) [4]. Hesperidin, and its aglycone hesperetin, have shown promising antioxidant and 
anticancer activity [5,6]. Furthermore, it has been implicated in several anticancer mechanisms, 
such as inhibition of angiogenesis, induction of apoptosis, cell cycle arrest, and modulation of 
regulatory proteins in cancer cells [7-9]. However, similar to most flavonoids, hesperidin has 
not yet been fully adopted, clinically, mainly due to its hydrophobic nature, resulting in poor 
bioavailability and low solubility in aqueous media [10,11]. Pharmacokinetic studies have 
shown that hesperidin is poorly absorbed and rapidly cleared, with less than 25% cumulative 
urinary recovery following oral administration, and non-detectable concentrations in 
circulating plasma after a single dose of 10 mg/kg in vivo [12,13]. Several lipid-based 
nanosystems, such as liposomes, solid lipid nanoparticles (SLN), microemulsions, micelles, 
and oil in water emulsions, have been reported as improving the solubility and bioavailability 
of flavonoids [14,15]. Additionally, hesperidin has previously been fabricated into a 
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chitosan/gelatin coated cargo known as hesperidin-loaded microparticles, hesperidin- 
PLGA/Poloxamer 407 nanoparticles and hesperidin-loaded solid lipid nanoparticles, to 
enhance its bioavailability, solubility, therapeutic effects and systemic circulation [16-18]. 
Furthermore, formulation of hesperidin into a nanosuspension demonstrated its enhancement 
due to the nanocrystalline formulation and not the micellar contribution of poloxamer 188 [19]. 
However, none of these studies, report on the nano emulsification of hesperidin or explore the 
use of polyethylene glycol (PEG) and Tween® 80 for the formulation of hesperidin 
nanoemulsions. Therefore, this study explores the use of Tween® 80, due to its self-emulsifying 
properties, safety and biocompatibility in cells, and PEG (a hydrophilic, non- toxic polymer) 
to formulate hesperidin-loaded nanoemulsions.   
Nanoemulsions are colloidal oil-in-water/water-in-oil dispersions, ranging from 20 to 500 nm 
in size, that are appropriate for use in the formulation of drug vehicles for hydrophobic 
molecules [20]. Nanoemulsions could be advantageous in improving the efficacy of hesperidin 
in cancer treatment due to their ability to escape rapid renal clearance, minimal adverse effects 
to neighbouring healthy cells, enhanced drug solubility and bioavailability, and improved 
absorption [21]. Furthermore, nanoemulsions improve specificity in drug targeting by 
exploiting the differences between tumour cells and normal cells. For example, in vivo, rapidly 
growing cancer cells are often characterized by leaky vasculature and a poor lymphatic 
drainage system. Nanoemulsions due to their size can be exploited to passively accumulate in 
the tumour microenvironment through the enhanced permeability and retention effect (EPR), 
thereby improving targeting and enhancing efficacy [22]. The vascular pore size for most solid 
tumours varies between 380 nm and 780 nm depending on the tumour type and growth. Thus, 
nanoemulsions with a particle size less than 400 nm can easily permeate into the tumour 
microenvironment and be retained for long periods [22,23].  
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Cancer is a complex disease characterized by uncontrolled cell proliferation, influenced by 
dysregulated cellular and molecular pathways. Until recently, these dysregulations were mostly 
accredited to abnormalities in oncogenes and tumour suppressor genes. However, currently, 
there is a focus on the posttranscriptional regulatory role of miRNAs, which modulate crucial 
signalling pathways related to apoptosis, cell cycle progression, and proliferation [24].  
Dysregulation of miRNAs has been implicated in the progression of carcinogenesis, and the 
aberrant expression of oncogenic miRNAs (oncomiRs), have been shown to influence tumour 
progression through suppressing apoptosis and allowing cell proliferation in various types of 
cancers [25]. Due to the ability of oncomiRs to act as oncogenes, they can be exploited as 
attractive therapeutic targets in cancer treatment. Overexpression of oncomiRs, miRNA-21 and 
miRNA-155 in breast and lung cancer has been implicated in cell differentiation, apoptosis, 
tumour progression and metastasis [26-29]. Previous in vitro studies have demonstrated that 
knockdown of miR-21 expression suppresses the growth and proliferation of cells in MCF-7 
[30]. Furthermore, inhibition of miR-155 in an allograft mouse model suppressed the growth 
of the breast tumour in mice, and knockdown of miR-155 in breast cancer cell lines decreased 
cell proliferation [31,32]. These reports support the inhibition of miR-21 and miR-155 as 
therapeutic targets in breast cancer treatment.   
Thus far, there are no known reports on the formulation of hesperidin into nanoemulsions, 
therapeutic potential of HP-NEM in breast cancer and epigenetic control. Therefore, this study 
evaluated the encapsulation of hesperidin into nanoemulsions, and compared the cytotoxicity 
of the optimised hesperidin-loaded nanoemulsions (HP-NEM) to hesperidin alone, in MCF-7. 
Thereafter, the effect of HP-NEM on apoptosis and cell cycle arrest in MCF-7, and the 
expression of oncomiRs (miR-21 and miR-155) was investigated.  
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Materials and Methods  
Chemicals  
Cell culture, dimethyl sulfoxide (DMSO), 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT), polyethylene glycol 2000 (PEG-2000), Tween® 80 and hesperidin 
were purchased from Sigma-Aldrich, Germany. Foetal bovine serum (FBS), Dulbecco’s 
phosphate-buffered saline (DPBS), Dulbecco’s modified Eagle’s medium (DMEM), and 
trypsin were obtained from Biowest, USA. Antibiotic-Antimycotic was obtained from Gibco 
by Life Technologies. Fresh sheep blood was purchased from Polychem Handelsges (South 
Africa). The kits used for the apoptosis and cell cycle analysis were obtained from BD 
Pharmingen™, California San Jose, USA. Purelink miRNA isolation kit (ThermoFischer 
Scientific, USA), SensiFast™ cDNA synthesis kit (Bioline, USA), SYBR green (Roche 
Diagnostics, IN, USA) and specific primers were synthesized from Inqaba Biotec™ 
laboratories, South Africa. All other reagents and solvents were of analytical grade.  
Synthesis of hesperidin-loaded nanoemulsions  
Hesperidin-loaded nanoemulsions (HP-NEM) were prepared based on a previously described 
spontaneous emulsification technique with some modifications [33]. Based on prior 
optimisation, 6.25 mg of hesperidin was dissolved in 1.25 mL of DSMO and sonicated for 30 
min. Thereafter, 50 mg of Tween® 80 dissolved in 1.25 mL of DMSO was added to the 
hesperidin solution and homogenised for 30 min at room temperature. Thereafter, 50 mg of the 
stabilizer, PEG-2000 dissolved in 5 mL, was added. The nanoemulsions were obtained on 
stirring the hesperidin and Tween® 80 mixture in 20 mL of water for 24 h.   
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Physico-chemical properties (particle size, polydispersity index (PDI), zeta-potential (ζ)) and 
morphology characterisation  
The particle size, polydispersity index (PDI), and zeta-potential (ζ) of the prepared HP-NEM 
diluted in deionised water in the ratio of 1:9 were obtained using a Zetasizer Nano ZS (Malvern 
Instruments Corp, UK) at room temperature. For the morphological characteristics, high 
resolution-transmission electron microscopy (HR-TEM) (Joel, JEM-1000, voltage of 100 kV) 
was used to capture the micrographs. The samples were prepared by the dropwise loading of 
the nanoemulsions onto a carbon-coated grid. These were allowed to dry then viewed using 
HR-TEM.    
Encapsulation efficiency  
The amount of hesperidin entrapped in the nanoemulsions was determined by a simple 
ultrafiltration method [34]. A 3 mL aliquot of nanoemulsions, with a calculated concentration 
of 250 µg/mL, was transferred into Amicon® Ultra-4 centrifugal filter tubes, pore size 10 kDa  
(Millipore Corp., USA), and centrifuged at 3000 rpm at room temperature for 30 minutes. 
Thereafter, the absorbance of the untrapped hesperidin, in the filtrate, was recorded at 280 nm 
using a Shimadzu UV-Vis 1601 (Japan) and calibration curve was employed to determine the 
amount of untrapped hesperidin. The encapsulation efficiency (EE) (percentage) was calculated 
from equation 1:  
Weight of hesperidin in the nanoemulsion 
EE % = ( ) × 100 … …. 𝐸𝑞. 1  
Weight of hesperidin initially added at preparation 
In vitro drug release   
For the drug release study, 1 mL of the prepared nanoemulsions was filled into a sealed dialysis 
bag with a molecular-weight-cut-off of 14 kDa and 8 mm in diameter. The dialysis bag was 
immersed into a bottle of the release medium which was phosphate buffer saline (PBS) at pH  
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7.4 (40 mL) and incubated at 37 °C on an orbital shaker maintained at 100 rpm [35]. At time 
intervals of 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, and 48 h, samples of 3 mL were collected and 
replaced with the same amount of fresh release medium to maintain sink conditions. The 
concentration of the HP-NEM in the collected samples was quantified spectrophotometrically 
at 280 nm using a Shimadzu UV-Vis 1601 (Japan), with suitable blanks. The cumulative release 
percentage was computed using the standard calibration curve and equation 2:  
  
% Cumulative release profile = (
𝐴𝑡
𝐴𝑖
) ×  100 %...................Eq. 2 
 
where At, is the amount of hesperidin released from HP-NEM at time t and Ai is the amount of 
hesperidin initially encapsulated into the nanoemulsions.  
Haemolysis assay  
The haemolysis assay was carried out to determine the blood compatibility of the prepared HP-
NEM. Firstly, the nanoemulsions were diluted to concentrations of 50, 100, 150, 200, and 250 
µg/mL in PBS (pH 7.4). Thereafter, 200 µL of fresh sheep blood was added to 800 µL of 
nanoemulsion at each concentration, followed by incubation at 37 °C for 1 h. PBS and pure 
water without the nanoemulsions served as the negative and positive controls, respectively. 
After incubation, the samples were centrifuged for 5 min at 10 000 rpm, and 200 µL of the 
supernatant was drawn and added to a 96-well plate. The absorbance was measured at 540 nm 
using a microplate reader (SPECTROstar Nano, BMG Germany). The percentage of  
haemolysis was calculated using equation 3:   
Absorbance (sample) − Absorbance (−ve control) 
Hemolysis % = ( ) × 10 …… 𝐸𝑞. 3  
Absorbance (+ve control) − Absorbance (−ve control) 
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Cytotoxicity  
Human breast cancer (MCF-7) cells and normal human (HEK 293) cells were obtained from 
the American Tissue Culture Collection (ATCC) (Virginia, USA). Cells were cultured in 
DMEM supplemented with 10% FBS and 1% antibiotic-antimycotic and incubated at 37 oC, at 
a humidified atmosphere of 5% CO2. When cells were in exponential growth, they were seeded 
into 96-wells plates (5 ˟ 103/100 µL of medium). The MCF-7 cells were treated with the 
hesperidin alone for 24 and 48 h or HP-NEM for 24 h at 20, 60, 100, and 140 µg/mL. The 
untreated cells served as the control in this experiment. To evaluate for selective cytotoxicity 
of the nanoemulsions, normal HEK 293 cells treated at the same concentrations for 24 h were 
used. After treatment, cell viability was determined by the colorimetric MTT assay with 
absorbance recorded at 560 nm. Following the cytotoxicity assay, the EC50 value of the 
nanoemulsions was determined.  
Apoptosis assay and cell cycle analysis  
The apoptosis analysis was conducted using flow cytometry and the BD Pharmingen™ 
Annexin V Apoptosis Kit 1, according to the manufacturer’s instructions. For cell cycle 
analysis, the BD Pharmingen™ FITC BrdU Flow Kit was employed. Briefly, treated cells were 
harvested, resuspended in 1 mL of medium, and labelled with 10 µL BrdU solution for 30 min 
at 37 oC.  Cells were fixed and permeabilized with BD cytofix buffer and cytoperm 
permeabilization buffer, respectively.  Fixed and permeabilized cells were treated with DNase 
at 37 oC for 1 h to expose the incorporated BrdU, then stained with anti-BrdU fluorescent 
antibodies. To stain for total DNA, 7-amino-actinomycin D (7-AAD) was subsequently added 
to the sample solution and incubated for 15 min at room temperature. Thereafter, the cell cycle 
analysis data was acquired using flow cytometry.  
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The quantitative real-time PCR analysis of miR-21 and miR-155  
MiRNA from the MCF-7 cells treated with the EC50 concentration and 100 µg/mL of the 
nanoemulsions or medium (control) for 24 h was extracted using the PureLink miRNA isolation 
kit as per the manufacturer’s instructions. The purity and concentration of the extracted miRNA 
were measured spectrophotometrically, with A260/280 ratio values greater than 1.8 considered 
as pure. The miRNA expression levels were detected using the synthesised cDNA template, 
SYBR green, and quantitative real-time PCR. The primer sequences used was as follows: miR-
21; forward 5′-GGGGATTTCTTGGTTTGTGAA-3′ and reverse 5′-
ATACAGCTAGAAAAGTCCCTGAAAA-3′ [36], and miR- 155; forward 5′- 
CGGTTTAATGCTAATCGTGA-3′ and reverse 5′-GAGCAGGGTCCGAGGT-3′ [37]. U6  
was used as the reference gene for the miRNA and to normalise the results. The comparative 
method was used to calculate the fold-change (FT) of miR-21 and miR-155 expression [38]; 
FT = 2-Δ ΔCq where Cq is the PCR cycle number in which the fluorescent signal from the 
amplification is detected.  
Statistical analysis  
All experiments were performed independently and in triplicate. Data was reported as the mean 
± standard deviation from the three experiments and evaluated for statistical significance by 
one-way ANOVA and Tukey`s post hoc tests at p < 0.05. Flow cytometry data was analysed 
using the Kaluza analysis software, version 2.1.   
  
Results  
Synthesis of hesperidin-loaded nanoemulsions (HP-NEM)  
Hesperidin-loaded nanoemulsions (HP-NEM) were successfully synthesised using the 
spontaneous emulsification method. Figure 1 illustrates the schematic formulation of the HP- 
NEM.  
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Figure 1. Formulation of hesperidin-loaded nanoemulsions (HP-NEM) (1) Drop-wise nano 
emulsification of hesperidin; (2) Formulation after 24 h stirring (3) As prepared hesperidin-loaded 
nanoemulsions (HP-NEM).  
Particle size, polydispersity index, zeta potential, and morphology  
Particle size has a substantial impact on drug delivery to tumours due to its effects on cellular 
uptake and internalization. Various studies suggest that smaller molecules and particles have 
ease of entry and prolonged retention in tumours [39]. Particles with an average diameter less 
than 500 nm can be internalised into cells through an endocytotic mechanism called pinocytosis  
[40]. Table 1 shows the particle size of HP-NEM as 305 ± 40.8 nm. The polydispersity index 
(PDI) (0.0 to 1.0) describes the degree of uniformity of particle size populations in a sample, 
with 0.0 indicating perfect particle size distribution and 1.0 indicating multiple particle sizes  
[40]. The PDI for HP-NEM was recorded as 0.308 ± 0.04 (Table 1). The zeta potential of the 
HP-NEM was recorded as -11.6 ± 3.30 mV (Table 1).   
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Table 1: Particle size, zeta potential, PDI and EE of hesperidin-loaded nanoemulsions. 
 
Hesperidin-loaded nanoemulsions physicochemical characteristics 
Size (nm) 305 ± 40.8 
Zeta Potential (mV) -11.6 ± 3.30 
PDI 0.308 ± 0.04 
EE % 93 ± 0.45 
Values represented as mean ± SD.   
The HR-TEM micrographs (Figure 2) show spherical nanoemulsions with moderate  
uniformity.  
  
  
Figure 2. The HR-TEM micrographs showing the prepared spherical hesperidin-loaded    
nanoemulsions (HP-NEM).   
Encapsulation efficiency  
The encapsulation efficiency (93 ± 0.45%) of the HP-NEM is also shown in Table 1. 
Encapsulation efficiency is a vital parameter in drug formulations, which indicates the loading 
efficiency of the formulation. The prepared nanoemulsions show relatively high encapsulation 
efficiency, suggesting greater incorporation of hesperidin into the nanoemulsions.   
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 In vitro drug release  
The drug release profile of hesperidin (hesperidin alone) and HP-NEM is shown in Figure 3. 
Hesperidin showed a significantly low drug release, with 16.05 % being released in the first 2 
h and slowing progressing to 26.66%, 36.29%, and 40.56 at 4 h, 8 h, and 24 h, respectively. In 
contrast, HP-NEM showed a higher release with, 24,85%, 45,93%, 86,90% and 97,34% of the 
hesperidin being release from the nanoemulsions at 2 h, 4 h, 8 h and 24 h respectively. Drug 
release from HP-NEM cumulated to 98.57 ± 0.39% (nearly complete drug release) over 48 h, 
compared to 46.35 ± 0.61% from hesperidin. The differences in the release rate could be due 
to insolubility of hesperidin in aqueous medium and the smaller particle size of the 
nanoemulsions, which could have improved their permeation across the membrane [41].  
  
  
Figure 3. The drug release profile of hesperidin and hesperidin-loaded nanoemulsions (HP-NEM) over 
48 h. Values represented as mean ± SD of three experimental replicates, * represents statistically 
significant difference of % cumulative drug release between hesperidin and hesperidin-loaded 
nanoemulsions at p < 0.05.  
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Haemolysis  
Haemolysis induced by new formulations or molecules is a significant limitation in their 
applications. Therefore, to ascertain the safety of the prepared HP-NEM, their in vitro 
haemolytic activity was assessed. The results shown in Figure 4 indicated that the haemolytic 
activity of the nanoemulsions at various concentrations was comparable to the negative control 
PBS, suggesting HP-NEM to be hemocompatible.   
  
  
Figure 4. The haemolytic activity of hesperidin-loaded nanoemulsions (HP-NEM). Experiments were 
done in triplicates, and values are represented as mean ± SD, *significant difference at p< 0.05.  
  
Cytotoxicity   
The in vitro cytotoxicity of hesperidin and  HP-NEM in MCF-7 cell lines is shown in Figure 
5a. Treatment with HP-NEM for 24 h showed significantly lower cell viability at all tested 
concentrations from 20 -140 µg/mL relative to hesperidin at 24 h or 48 h. HP-NEM was most 
effective at concentrations of 60 to 140 µg/mL, decreasing cell viability to less than 10%. Based 
on these results, prolonged incubation for the nanoemulsions was not necessary, and all 
treatments, thereafter, were conducted at 24 h. The EC50 concentrations of hesperidin and HP-
NEM in MCF-7 at 24 h were determined as 62.57 µg/mL and 29.36 µg/mL, respectively.  
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Hesperidin and HP-NEM showed low toxicity against normal HEK 293 cells (Figure 5b).  
  
  
Figure 5. The comparative cytotoxic effect of hesperidin and hesperidin-loaded nanoemulsions (HP-
NEM) against (a) MCF-7 and (b) HEK 293, untreated cells served as the control. Values represented as 
mean ± SD of three independent experimental replicates, * significant difference from the untreated 
group at p< 0.05 and # significant difference from the hesperidin 24 h treated group at p< 0.05. 
 
Apoptosis  
Following the cytotoxicity analysis, hesperidin and HP-NEM were further evaluated, to 
examine whether the induced cell death in MCF-7 was through apoptosis. Annexin and PI 
staining were used to evaluate the apoptotic activity. Treatment of MCF-7 cells with 100 ug/mL 
of hesperidin and HP-NEM for 24 h significantly increased the total percentage of apoptotic 
cells from 0.01% in the control (untreated cells) to 18.80% and 58.87%, respectively (Figure  
6). This confirmed the induction of apoptosis in MCF-7 after treatment with hesperidin and  
HP-NEM, and potent efficacy of HP-NEM in comparison to hesperidin.  
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Figure 6. The apoptotic effect of (a) hesperidin and (b) hesperidin-loaded nanoemulsions (HP-NEM) 
on MCF-7 at 100 µg/mL for 24 h treatment. Quadrants represent A--, viable, A-+, early apoptotic, A++, 
late apoptotic, and A+-, necrotic cells. The bar chart represents the mean total percentage of the 
apoptotic cells’ population. Values represented as mean ± SD of three independent experiments, 
*significant difference from the control at p< 0.05.  
 
Cell cycle analysis  
Figure 7 shows the cell cycle distribution of MCF-7 cells after treatment with 100 µg/mL of 
hesperidin and HP-NEM for 24 h. Compared to the control (untreated cells), hesperidin treated 
cells showed an increased percentage accumulation in the G0/G1 (38.72%), S (16.98%), and 
G2/M (25.12%) phases. However, HP-NEM treated cells showed an increased percentage 
accumulation in the G0/G1 (32.34%), S (6.4%), and G2/M (45.30%) phases. Higher 
accumulation in the G0/G1 phase (38.72%) and G2/M phase (45.30%) suggests cell cycle arrest 
in the G0/G1 and G2/M phase for hesperidin and HP-NEM, respectively.   
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Figure 7. The effect of (a) hesperidin and (b) hesperidin-loaded nanoemulsions (HP-NEM) on cell 
cycle in MCF-7 after 24 h treatment at 100 µg/mL. The bar chart represents the mean percentage of cell 
populations in cell cycle phases G0/G1, S and G2/M. Values represented as mean ± SD of three 
experiments, * significant difference at p< 0.05. 
  
miRNAs expression in HP-NEM treated MCF-7  
To evaluate the potential of HP-NEM as a therapeutic agent in breast cancer, its effect on miR21 
and miR-155, oncomiRs overexpressed in breast cancer [42], was investigated. The effect of 
HP-NEM on miR-21 and miR-155 expression in MCF-7 is illustrated in Figure 8. The results 
showed that the treatment of the MCF-7 cells with HP-NEM at concentrations of 29. 36 µg/mL 
(EC50) and 100 µg/mL for 24 h, significantly decreased miR-21 and miR-155 expression 
relative to the control (untreated cells) at p < 0.05.  
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Figure 8. Hesperidin-loaded nanoemulsions (HP-NEM) downregulates miR-21 and miR-155 
expression in MCF-7 after treatment at concentrations of 29.36 µg/mL (EC50) and 100 µg/mL for 24 h. 
Values represented as mean ± SD of three experimental replicates, and *,# significant difference from 
the control group and HP-NEM 100 µg/mL at p< 0.05, respectively. 
  
Discussion  
The pharmacological use of hesperidin, a natural plant-based flavonoid, with potential 
neuroprotective, inflammatory, and anticancer activities (including promoting apoptosis as 
well as limiting tumour progression, metastasis and cell proliferation) [6,43], is hampered by 
low water solubility and poor bioavailability [11]. Nanoemulsions are widely accepted as an 
ideal delivery system for enhancing solubility and bioavailability of hydrophobic compounds 
[44]. Nanoemulsions have gained substantive recognition due to their stability, prolonged half-
life, ability to protect drugs from enzymatic degradation, and non-toxicity [21]. However, the 
incorporation of hesperidin into nanoemulsions has not been studied.   
In this study, we successfully synthesised hesperidin-loaded nanoemulsions (HP-NEM) with 
an average size of 305 nm and an encapsulation efficiency of 93% from an initial concentration 
of 250 µg/mL of the nanoemulsions. Characterisation of HP-NEM with HR-TEM confirmed 
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the spherical morphology (Figure 2), with moderate particle uniformity, indicated by a PDI 
value of 3.08 (Table 1). The net surface charge of nanoemulsions is reported to enhance drug 
stability, membrane permeation and efficacy [45] and in this regard, HP-NEM exhibited a 
negative surface charge of -11.6 mV (Table 1), contributing to the stability of HP-NEM, 
through electrostatic repulsion between particles. Furthermore, the negative surface charge has 
been reported to decrease binding to serum proteins and prolongs circulation [46]. The 
circulating half-life of nanoemulsions plays a critical role in their efficacy and studies have 
shown that coating nanoparticles with hydrophilic polymers such as polyethylene glycol 
(PEG), could prevent non-specific interactions and rapid renal clearance, as well as prolong the 
circulating half-life thereby improving efficacy [22]. In particular, long PEG chains such as 
PEG-2000 or PEG-5000, integrated into nanoemulsions, have been shown to improve their 
retention time and tumour circulation [47].   
The ability of nano formulations to release its cargo at specifically targeted sites or over time 
for sustained medication, is also important for its efficacy as a delivery system [48]. The in 
vitro release profile (Figure 3) showed that both hesperidin and HP-NEM exhibited a sustained 
release pattern, with HP-NEM displaying a significantly higher cumulative release of 98.57 ± 
0.39% in comparison to 46.4 ± 0.60% for hesperidin, over a 48 h period. The higher release of 
hesperidin from HP-NEM could be attributed to improved solubility resulting in increased 
diffusion through the membrane. These findings were similar to those previously reported on 
enhanced hydrophobic drug dissolution in eplerenone nanoemulsions, which resulted in a 
higher (90%) and sustained release from the nanoemulsions in contrast to the unformulated 
drug (39.6%) [49].   
The efficacy of HP-NEM as an anticancer agent was determined through a comparative 
cytotoxicity study between hesperidin and HP-NEM in MCF-7. Hesperidin and HP-NEM 
showed dose and time-dependent cytotoxicity, with HP-NEM showing significantly higher 
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cytotoxic effects within a shorter incubation period, 24 h (Figure 5a). The potency of HP-NEM 
to induce cytotoxicity in MCF-7 was further confirmed by the EC50 values, where encapsulation 
of hesperidin reduced the EC50 value by half (62.57 µg/mL for hesperidin vs. 29.36 µg/mL for 
HP-NEM). Solubility and size could have possibly contributed to the more potent cytotoxicity 
of HP-NEM (particle size of 305 nm) in comparison to hesperidin (particle size of 1320 nm) 
[16]. Similarly, encapsulating kaempferol into nanoemulsions showed a significantly higher 
decreased cell viability in glioma cells (brain cancer) when compared to free kaempferol [50]. 
Furthermore, the safety of HP-NEM was supported by the lack of induction of haemolysis in 
red blood cells (Figure 4) and low toxic effects against normal HEK 293 cell lines (Figure 5b).   
Induction of apoptosis is regarded as a vital strategy in cancer treatment [51], hence following 
the observed potent cytotoxicity of HP-NEM in MCF-7 cells, the form of cell death was further 
investigated. Several cell death mechanisms, including apoptosis, autophagy, and necrosis, 
have been implicated in drug cytotoxicity effects in cancer cells, with apoptosis being the target 
for most treatments [45]. Cells undergoing apoptosis have phosphatidylserine (PS), an 
apoptotic marker that binds to Annexin V externalised, and thus serves as a probe for flow 
cytometric analysis for apoptotic cells [52]. In addition, Annexin V is conjugated with 
propidium iodide (PI) to distinguish between apoptotic cells (PI-negative) and necrotic cells 
(PI-positive). In this study, the induction of apoptosis by hesperidin and HP-NEM in MCF-7 
was confirmed through Annexin V/PI and flow cytometry, 24 h post-treatment.  HP-NEM 
treated cells showed a higher increase in the total accumulation of apoptotic cell populations 
from the control, 58.87% versus 18.80% in hesperidin treated cells. This result further 
confirmed the potency of HP-NEM over hesperidin in MCF-7.   
Cell cycle dysregulation associated with uncontrolled cell propagation and genomic instability, 
is one of the major characteristics of cancer. Regulation of cell cycle progression or cell cycle 
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arrest (stopping in-phase until DNA is repaired or cells undergo apoptosis) is regarded as an 
effective approach in tumour growth control [53]. In this study, HP-NEM demonstrated 
significant accumulation of apoptotic cell populations in the G2/M phase after 24 h treatment, 
which suggests that cell cycle arrest is one of the mechanisms HP-NEM employs to effect 
cytotoxicity in MCF-7. These results were consistent with other plant-based nanoemulsions, 
such as carvacrol (from thyme plants) which induced apoptosis and cell cycle arrest in 
doxorubicin-resistant A549 cell lines (lung cancer) [54].   
Studies on post-transcriptional gene regulators, miRNAs, has revolutionised our understanding 
of cancer biology [55]. The regulatory role played by miRNAs in the progression of cancer has 
enhanced their potential as therapeutic targets in cancer treatment [56]. Examples of successful 
miRNA-targeting drugs in clinical trials include Miravirsen, which inhibits miR-122 
responsible for viral replication in hepatitis C [57]; MRG 110, which inhibits miR-92 mostly 
overexpressed in non-small-cell-lung cancer; and RGLS5579 targeted miR-10b, which 
promotes metastasis in brain cancer [58].  Previous studies have reported the upregulation of 
miR-21 and miR-155 in breast cancer [28]. Therefore, targeting miR-21 and miR-155 could 
provide a possible new therapeutic approach in breast cancer.  The effect of HP-NEM on 
oncomiRs has not previously been reported. In this study, we evaluated the expression of miR- 
21 and miR-155 in MCF-7 after treatment with HP-NEM for 24 h, using real-time PCR. 
HPNEM downregulated the expression of miR-21 and miR-155, supporting its therapeutic 
potential in breast cancer treatment.   
Conclusion  
Although hesperidin has experimentally shown potential therapeutic effects, its efficacy is 
hampered due to its hydrophobic nature and low bioavailability. This study shows 
encapsulation of hesperidin into nanoemulsions could improve its efficacy in breast cancer 
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treatment, as demonstrated by the significantly higher cytotoxicity of hesperidin-loaded 
nanoemulsions (HP-NEM) against MCF-7 compared to hesperidin. HP-NEM induced  
cytotoxicity in MCF-7 through apoptosis and cell cycle arrest in the G2/M phase and was found 
to be safe with no adverse side effects. Furthermore, this study shows the potential of HP-NEM 
as a therapeutic agent in breast cancer treatment by inhibiting the overexpressed miR-21 and 
miR-155 in MCF-7, which has never been reported before. Future studies on the mechanisms 
underlying the inhibition of oncomiRs by HP-NEM and the pharmacokinetics of HP-NEM are 
further required to assess its therapeutic potential in breast cancer.    
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 5.  CHAPTER FIVE: SUMMARY  
  
5.1 Synthesis  
  
The plant kingdom continues to make significant contributions to modern medicine, offering 
structurally diverse compounds with a plethora of therapeutic effects and providing new entities 
for drug discovery and development. Currently, of the approximately half a million discovered 
world flora species, only 10% has been scientifically investigated. Historically, research into 
natural medicinal plants has given rise to potent anticancer drugs. Indeed plant-derived 
compounds as an alternative therapeutic approach has gained enormous momentum in cancer, 
targeting apoptotic pathways with a purported lower toxicity to cells. However, there remains 
an extensive gap between the scientific validation of promising plant-derived compounds and 
the biodiversity of the natural flora.  
Optimised, selective therapeutic effects on cancerous cells with minimal toxicity on healthy 
cells is urgently required in current therapies. Nanotechnologically modified drugs and drug 
delivery systems have emerged as attractive entities in cancer treatment offering site-specific 
drug delivery, improved drug bioavailability and solubility. The incorporation of plant-derived 
compounds into novel nanotechnology systems could improve their pharmacokinetic 
limitations, target specificity and therapeutic effects. Therefore, this study aimed to isolate and 
characterise phytocompounds from Eriocephalus africanus L., investigate their effect on 
apoptotic and epigenetic control in breast cancer using human breast adenocarcinoma cell lines 
(MCF-7), and develop nanosystems for their encapsulation and explore their safety and efficacy 
as anticancer agents.  
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Figure 9. Schematic presentation of the study.   
The phytochemical analysis of the methanolic extracts of E. africanus resulted in the isolation 
and identification of hesperidin, luteolin and apigenin. Preliminary screening of the methanolic 
extract and isolated compounds for anticancer activity in selected human carcinoma cell lines 
(MCF-7, HepG2 and A549), showed decreased cell viability in a dose dependent manner. 
Interestingly, the methanolic extract showed the highest effect against MCF-7 with EC50 of 
45.47 µg/mL in contrast to the pure isolated compounds, which recorded EC50 values of 62.57 
µg/mL for hesperidin, 70.34 µg/mL for luteolin and > 100 µg/mL for apigenin, demonstrating 
synergistic effects of the compounds. Hesperidin and luteolin, which demonstrated potential 
anticancer activity, were further investigated for their cytotoxicity in MCF-7, a model which 
represents luminal A breast cancer. The non-cancerous human embryonic kidney cells (HEK 
293) are widely used in biomedical research as they are representative of healthy human cells 
and are easy to grow and maintain; therefore, they were used as a model in this study to evaluate 
the selective toxicity of the isolated compounds. The isolated compounds showed selective 
toxicity against HEK 293, with minimal decrease in cell viability in the order of hesperidin > 
luteolin > apigenin. This study revealed the methanolic extract of E. africanus to be a rich 
source of natural flavonoids, with major flavonoids being hesperidin, luteolin and apigenin.  
Subsequent to profiling the cytotoxic effects demonstrated by hesperidin and luteolin in MCF7, 
we evaluated their effects on key molecular pathways implicated in the pathophysiology of 
breast cancer and cancer per se. Evasion of apoptosis is a hallmark of all cancers, including 
breast cancer, and is associated with uncontrolled tumour progression, metastasis and resistance 
to therapy. In this regard, recent drug developments have been focusing on anticancer agents 
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with the potential to induce or repair apoptotic function.  Hesperidin and luteolin demonstrated 
MCF-7 cell death induced by apoptosis through the intrinsic and extrinsic pathways coupled 
with downregulation of antiapoptotic Bcl-2 expression and upregulation of proapoptotic Bax 
expression. Dysregulated cell cycle machinery has also been indicated to promote tumour 
progression, hence therapeutic agents inhibiting the progression of cancerous cells through the 
cell cycle are of great importance in cancer treatment. In this regard, the effects of hesperidin 
and luteolin on cell cycle progression were evaluated and found to cause accumulation of cell 
populations in the G0/G1 and sub-G1 phases, respectively.   
In light of the emerging evidence on the vital role of miRNA as post-transcriptional gene 
expression regulators through binding to target mRNA, we evaluated the expression of key 
apoptotic miRNA (viz. miR-16, -21 and -34a), upon treatment with hesperidin or luteolin. In 
addition, their relationship with the expression of target Bcl-2 gene was evaluated. The findings 
from quantitative real-time PCR analysis revealed that treatment of MCF-7 with hesperidin or 
luteolin resulted in downregulation of miR-21 and upregulation of miR-16 and -34a. 
Furthermore, Pearson`s correlation analysis indicated positive correlation between the 
expression of Bcl-2 and miR-21 and negative correlation between Bcl-2, miR-16 and -34a, 
indicating that treatment with flavonoids promote apoptosis through upregulation of 
proapoptotic miRNAs and downregulation of Bcl-2. Overall, findings from this study 
broadened the understanding of molecular mechanisms involved in flavonoid-induced cell 
death and provided new insights on their effects on expression of apoptotic miRNAs as well as 
their relations with target mRNA.    
Nanotechnology was employed to improve the bioavailability and efficacy of hesperidin and 
luteolin. Hesperidin was successfully encapsulated into a nanoemulsion (HP-NEM), prepared 
using Tween® 80, PEG-2000 and water via a spontaneous emulsification technique. The 
prepared HP-NEM displayed a spherical shape with 305 nm, 0.308 and -11.6 mV and 93% for 
particle size, polydispersity index (PDI), zeta-potential (ζ) and encapsulation efficiency, 
respectively. Biosafety studies of HP-NEM performed through the MTT assay on HEK 293 
together with a haemolytic assay, revealed the safety profile of HP-NEM. Exposure of MCF-7 
cells to HP-NEM for 24 h, showed significantly lower cell viability at all tested concentrations 
from 20 -140 µg/mL relative to hesperidin at 24 h or 48 h, confirming enhanced cytotoxicity. 
This cytotoxicity was confirmed to be through induction of apoptosis using flow cytometric 
techniques. Furthermore, treatment of MCF-7 cells with HP-NEM resulted in accumulation of 
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cell populations in the G2/M of the cell cycle. Of note, treatment with hesperidin alone and 
HP-NEM resulted in cell accumulation at different phases G0/G1 and G2/M, respectively. This 
could suggest that the modification of hesperidin into HP-NEM influences activation of 
possibly different cell cycle signaling factors to that of hesperidin alone, resulting in halting of 
the cell cycle progression at different phases. Nevertheless, more details still need to be 
determined and investigated. miR-21 and miR-155 have been described as oncomirs 
overexpressed in breast cancer that influence tumour progression. In this study, treatment of 
MCF-7 with HP-NEM for 24 h downregulated the expression of miR-21 and miR155, 
showcasing the novelty of HP-NEM as a potential therapeutic agent in breast cancer treatment. 
An interesting finding was that treatment with the EC50 concentration (29.36 µg/mL) of HP-
NEM resulted in further decreased expression of miR-21, in contrast to treatment at a 
concentration of 100 µg/mL. This may suggest that HP-NEM has a higher binding affinity to 
miR-21 at low concentrations, which resulted in the observed higher inhibition of miR-21 
expression and could further contribute to its therapeutic potency in breast cancer treatment as 
an inhibitor of miR-21. 
As part of our standardisation procedures we also investigated the synthesis, physicochemical 
properties and cytotoxic activity of luteolin-loaded solid-lipid nanoparticles (Appendix A). For 
the encapsulation of luteolin, solid-lipid nanoparticles generated from cleaved stearylamine 
were used. Solid-lipid nanoparticles are similar to nanoemulsions, but they employ a solid lipid 
instead of a liquid lipid as in the case of nanoemulsions. Luteolin-loaded solid-lipid 
nanoparticles (LUT-SA-SLN) were successfully formulated using an emulsion-solvent 
evaporation method and evaluated for their biosafety in HEK 293. Exposure of HEK 293 to 
LUT-SA-SLN, reduced cell viability drastically (< 10 %) at all tested treatments and several 
experimental replicates. These observations indicated that LUT-SA-SLN exhibited non-
selective cytotoxicity and their use could cause adverse side effects therefore, no further 
experiments were conducted using LUT-SA-SLN, in this study.   
 
5.2 Conclusion  
  
Overall, findings presented in this study provide comprehensive insight into the anticancer 
potential of E. africanus from plant extract to nanodrug. The study identifies E. africanus as a 
source of natural flavonoids, possessing anticancer therapeutic effects mediated through the 
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apoptotic pathway and cell cycle regulation. This study provides new insight on the effects of 
flavonoids on the expression of apoptotic miRNAs, demonstrating their efficacy in targeting 
apoptosis in cancer treatment. The encapsulation of the flavonoids into newly designed 
nanosystems, highlights the potential of improved bioavailability and therapeutic efficacy of 
hesperidin-loaded nanoemulsions in breast cancer treatment mediated through apoptotic 
activity and downregulation of commonly overexpressed oncomirs. Importantly, this study 
makes a significant contribution in broadening the scientific basis for the potential use of plant-
derived, nanotechnologically-modified flavonoids as alternative treatment options in breast 
cancer.  
  
5.3 Recommendations for further work  
  
In this study, apigenin proved to be less sensitive against MCF-7; however, it showed potent 
activity against HepG2 (EC50 = 11.93 µg/mL), therefore it could be explored for possible 
treatment of liver cancer.  
  
The use of plant-derived flavonoids and flavonoid-loaded nanosystems in targeting the 
apoptotic pathway for breast cancer treatment promises to circumvent the challenges in current 
therapies. However, further research is needed to replicate the in vitro model represented in 
this study to further understand their use in cancer treatment. In this regard the following 
recommendations are proposed:  
• Investigate the effects of flavonoids and flavonoid-loaded nanoemulsions in other in 
vitro and in vivo cancer models and comprehensively investigate the pathways 
implicated in the pathogenesis and treatment of cancer  
• Perform in vivo studies and evaluate the pharmacokinetics, toxicity and degree of 
accumulation at the diseased site of the synthesised flavonoid-loaded nanosytems  
• Functionalise and optimise the synthesised flavonoid-loaded nanosystems for possible 
clinical application in breast cancer treatment.  
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    APPENDICES 
Appendix A 
Luteolin-loaded solid lipid nanoparticles  
Synthesis of the novel lipid used for the encapsulation of luteolin  
The bicephalic surfactant (novel lipid) was synthesised as illustrated in Scheme A1.  
  
Scheme A1. a). Methanol (MeOH), reflux with constant stirring at 80 oC, 24 h, and b). MeOH 
+ trifluoroacetic acid (TFA)/triisopropylsilane (TIPS) at room temperature for 8 h.  
Synthesis of Compound 3 (di-tert-butyl 3,3'-(octadecylazanediyl) dipropionate)  
Compound 3 was synthesised following a previously reported procedure (Hassan et al. 2020). 
Briefly, tert-butyl acrylate 2 (1.75 g; 13.65 mmol) was dissolved in methanol (15 mL) and the 
solution was added to stearylamine 1 in methanol (1.7 g; 6.3 mmol) (10 mL). The mixture was 
stirred and refluxed at 80 oC for 24 h and the progress of the reaction was monitored via thin 
layer chromatography. The crude product was washed with chloroform several times to remove 
excess tert-butyl acrylate (BA), then the solvent (chloroform) and excess BA were removed 
using a rotary evaporator. The crude product was purified via column chromatography (silica, 
mesh size 60 - 100) (hexane: ethyl acetate, 7: 3) to obtain a white solid compound 3 (1.85 g; 
yield 49.52 %).  
Synthesis of Compound 4 (3, 3'-(octadecyl-azanediyl) dipropionic acid)  
To a solution of compound 3 (1.03 g; 0.46 mmol) in methanol (20 mL), TFA/TIPS (1.81g; 23 
mmol) was added at room temperature, as reported in the literature (Makhathini et al. 2019). 
The resulting mixture was stirred vigorously at room temperature for 6 h and evaporated to 
dryness using a rotary evaporator. The subsequent residue was washed several times with 
hexane to obtain a white semi-white compound 4 (SA) (0.28 g; yield 56.45 %).  
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Synthesis of luteolin-loaded solid lipid nanoparticles (LUT-SA- SLN)  
The luteolin-loaded solid lipid nanoparticles (LUT-SA-SLN) were prepared using the 
emulsion-solvent evaporation method (Umerska et al. 2018). Briefly, luteolin and the novel 
lipid (SA) were both dissolved in tetrahydrofuran (THF) separately and added dropwise to 
deionized water under ultrasound sonication. Thereafter, the solution was gently stirred using 
a magnetic stirrer at room temperature for 24 h, to allow for solvent evaporation and formation 
of the nanoparticles (Figure A1).   
  
Figure A1. Synthesis of luteolin-loaded solid lipid nanoparticles (LUT-SA-SLN) using the emulsion-
solvent evaporation method.  
Physicochemical properties of the synthesised LUT-SA-SLN  
The particle size, polydispersity index, zeta potential, and the encapsulation efficiency of LUT- 
SA-SLN is shown in Table A1  
Table A1. Particle size, zeta potential, PDI and EE of luteolin-loaded solid lipid nanoparticles.  
 
Luteolin-loaded solid lipid nanoparticle physicochemical characteristics  
Size (nm)  227.1 ± 53.98  
Zeta Potential (mV)  -30.4 ± 5.51  
PDI  0.371 ± 0.08  
EE %  95 ± 0.01  
Values represented as mean ± SD.   
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Morphology  
The morphology of the synthesised luteolin-loaded solid lipid nanoparticles recorded using the  
HR-TEM, was shown to be spherical in shape (Figure A2)  
  
Figure A2. HR-TEM micrographs of synthesised luteolin-loaded solid lipid nanoparticles  
In vitro drug release  
The drug release study was carried out as described in Chapter four, manuscript three. The 
drug release profile for luteolin and LUT-SA-SLN (Figure A3), showed a rapid drug release 
from luteolin with up 94% released in the first 8 h. In contrast, LUT-SA-SLN showed a slower 
drug release with 60% released in the first 8 h then progressing to plateau at 86% from 24 h to 
48 h. Previous studies have attributed the slower release to internal interactions between the 
encapsulated drug and the polymer of the nanoparticles (Cristina Puhl et al. 2011). 
Furthermore, similar luteolin release was observed for stearylamine-chitosan nanoparticles 
(Dang et al. 2014).  
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Figure A3. The drug release profile of luteolin and luteolin-loaded solid lipid nanoparticles (LUT-
SA-SLN) over 48 h. Values represented as mean ± SD from experimental triplicates, * represents 
statistically significant difference of % cumulative drug release between luteolin and luteolin-loaded 
solid lipid nanoparticles at p <0.05.  
Cytotoxicity of LUT-SA-SLN   
Based on the calculated concentration (5 µg/mL) of luteolin in the synthesised nanoparticles, 
cells (MCF-7 and HEK 293) were treated with LUT-SA-SLN in dilutions of 20, 40, 60, and 
100 µL in  supplemented DMEM (100 µL, total volume per well), 5- fluorouracil (5-FU) served 
as the positive control in this experiment. The cell viability was determined by the colorimetric 
MTT assay with absorbance recorded at 560 nm. As illustrated in Figure A4, treatment with 
LUT-SA-SLN, resulted in decreased cell viability of < 10% in both cell lines, indicating the 
non-selective toxicity of the prepared LUT-SA-SLN.  
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Figure A4. Cytotoxicity of luteolin-loaded solid lipid nanoparticles (LUT-SA-SLN) against (a) HEK 
293, (b) MCF-7 and (c) comparison of LUT-SA-SLN cytotoxicity in HEK 293 and MCF-7. Values 
are represented as mean ± SD of six experimental replicates.  
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